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Introduction
Kidney disease is a common disorder that affects around 60.000 people in the 
Netherlands only (in 2011)1. In the US, up to 10% of the population is affected 
and this number is rising2. In the Netherlands, 15.985 people are dependent 
on renal replacement therapy, involving either dialysis or, ideally, kidney 
transplantation. In 2011, 9663 people were living with a kidney transplant 
while 6322 people were on dialysis, of which 989 undergo peritoneal dialysis 
and 5333 hemodialysis. Every year, 20% of people that are on dialysis die from 
complications1, of which cardiovascular disease is the leading cause of death 
in patients with chronic kidney disease3. In 2011, 855 kidney transplantations 
were performed, of which 436 donor kidneys were derived from living donors 
and 419 kidneys post mortem. The number of people that are on the waiting 
list for a transplant kidney is 883 and the average waiting time for receiving 
a donor kidney (post mortem) is 4 years1. These numbers indicate the severity 
of problems caused and number of people affected by kidney disease. It is 
therefore highly relevant to understand the biological mechanisms that are 
involved in kidney pathophysiology. This thesis covers several aspects of 
kidney (dys)function, and in particular its regulation by microRNAs.
Figure 1. Schematic illustration of a kidney with important anatomic structures 
highlighted. From: Brenner, B.M. Brenner & Rector’s The Kidney, Elsevier (2004).
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The Kidney
Kidneys are retroperitoneal organs situated in the posterior part of the 
abdomen on each side of the vertebral column. The right kidney is usually 
positioned slightly more caudal. In an adult human, the weight of a kidney 
ranges from 115 to 170 grams and is 11-12 cm. long, 5 to 7.5 cm wide and 
2.5 to 3 cm thick. Located on the medial surface is a hilus, through which 
the renal artery and vein, the lymphatics and a nerve plexus enter the kidney.
The parenchyma consists of the tubular system, the interstitium and the 
vasculature and can be divided into cortex (outer region) and medulla (inner 
region) (Figure 1). In humans, the medulla is divided into 8 to 18 striated 
conical masses, the renal pyramids. In contrast to humans, mice only have 
one renal pyramid. The base of each pyramid lies on the corticomedullary 
boundary and the tip extend towards the renal pelvis, forming a papilla. On 
the tip of a papilla 10 to 25 small openings can be found that are the ends of 
the collecting ducts. The cortex is around 1 cm thick and forms a cap over the 
base of the renal pyramids. At the tips of the pyramids, urine is formed and 
4. 
Figure 2. Schematic illustration of a nephron. Adapted from: cellular pathophysiology of ischemic 
acute kidney injury, JV Bonventre and L Yang, J Clin Invest, 2011.
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The functional unit of the kidney is the nephron5 (Figure 2). The human 
kidney contains about 0.4 to 1.2 x 106 nephrons6,7. Their main function is to 
regulate the concentration of water and preservation of soluble substances 
excreting the rest as urine. A nephron eliminates waste products from the 
body, regulates blood pressure, controls levels of electrolytes and metabolites, 
and regulates blood pH. Its functions are partly regulated by the endocrine 
system by different hormones while the kidney itself also produces hormones. 
The nephron consists of the renal corpuscle (glomerulus and Bowman’s 
capsule, Figure 3) connected to the renal tubular system and ending in the 
barrier between the blood and urinary space is composed of a fenestrated 
endothelium, glomerular basement membrane and the slit pores between the 
foot processes of the podocytes. In the center of the capillary tuft lies the 
mesangium, which consists of mesangial cells and extracellular matrix and 
forms the structural basis of the capillary tuft. Filtration is dependent on blood 
pressure and velocity, physical-chemical characteristics of compounds in the 
blood and permeability of the capillary wall. Blood enters the glomerulus 
through the afferent arteriole while it is leaving via the efferent arteriole. 
The dynamic interplay between these arterioles forms the basis of the 
autoregulation of the kidney in a specialized region called the juxtaglomerular 
apparatus (Figure 3). 
This apparatus consists of juxtaglomerular cells, macula densa and 
extraglomerular mesangial cells8. The juxtaglomerular cells (specialized 
smooth muscle like cells) are situated in the afferent arteriole, right beneath 
the endothelial cells, and contain the hormone renin9,10. The macula densa 
consists of epithelial cells from the cortical part of the thick ascending limb. 
9
the space between afferent en efferent arteriole and the macula densa11. The 
relation between these cells, all belonging to the same nephron, is crucial to 
regulation of the blood volume12
salt levels in the tubules are lowered. This is registered by the macula densa 
which stimulates renin secretion by the juxtaglomerular apparatus13. Renin 
activates the renin-angiotensin-aldosterone system (RAAS; Figure 4) that 
regulates and maintains blood pressure and volume. In addition, the cells 
of the macula densa sense changes in in luminal salt concentrations14. This 
initiates the tubuloglomerular feedback response that results in constriction 
or dilation of the afferent arteriole, thereby controlling the glomerular 
1
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production13.
In the urinary pole of the glomerulus, the tubular system starts, that 
extends from the cortex to the medulla and back to the same glomerulus 
(juxtaglomerular apparatus). In the tubules, water and other solutes are 
while some other compounds from these capillaries are secreted into this 
pre-urine. 
The proximal tubule can be divided into an initial convoluted portion (pars 
Figure 3. Schematic illustration of the renal corpuscle. Adapted from: Medical Illustrations, 
Michal Komorniczak (Poland). 
A – Renal corpuscle   4. Bowman’s space (urinary space) 
B – Proximal tubule   5a. Mesangium – Intraglomerular cell 
C – Distal convoluted tubule  5b. Mesangium – Extraglomerular cell 
 
1. Basement membrane (Basal lamina) 7. Macula densa 
2. Bowman’s capsule – parietal layer  8. Myocytes (smooth muscle) 
3. Bowman’s capsule – visceral layer  9. Afferent arteriole 
 
3b. Podocyte    11. Efferent arteriole
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salt and water and organic solutes (primarily glucose and amino acids) is 
reabsorbed here4. Fluid reabsorption is coupled to active transport of Na+, 
and little changes occur in the osmolality or Na+ concentration of the tubular 
15. 
The loop of Henle is a U-shaped tube that extends from the proximal tubule. 
It consists of a descending limb and ascending limb. The thin limbs of Henle 
play an important role in the countercurrent multiplication process that is 
responsible for the maintenance of a hypertonic medullary interstitium and 
for the dilution and concentration of the urine16,17. The thin descending 
limb is permeable to water but has low permeability to salts18
descends deeper into the hypertonic interstitium of the renal medulla, water 
thin ascending limb is largely impermeable to water, but highly permeable to 
salts, which causes salts to diffuse out of the tubule. 
The loop of Henle is supplied by blood in a series of straight capillaries 
descending from the cortical efferent arterioles19. These capillaries (the vasa 
recta) are highly permeable to water and solutes and easily take up the water 
and salts that were resorbed by the thin limbs. Due to this, the osmolality of 
the vasa recta is almost equal to that of the medullary interstitium. Therefore 
it is essential that the vasa recta has a hairpin turn in the medulla and leaves 
the medulla at the cortical side. If it would leave at the papillary side, they 
would wash out the osmotic gradient20. 
Figure 4. Schematic representation of renin-angiotensin-aldosterone-system.
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thick ascending limb, macula densa and distal convoluted tubule. Cells lining 
the distal tubule have numerous mitochondria to produce energy (ATP) to 
accomodate active transport, that mainly involves reabsorption of sodium 
and chloride21,22.   
collecting duct system begins in the renal cortex and extends deep into the 
medulla to end in the tip of the papilla. The epithelium of the collecting duct 
is relatively impermeable to water in the absence of antidiuretic hormone 
(ADH or vasopressin). In the presence of ADH, all segments of the collecting 
duct become water permeable23. ADH affects the localization of the water 
channel aquaporin-224, resulting in the reabsorption of water molecules, 
while preventing the passage of ions and other solutes. Increased ADH is an 
for diluted urine. 
Finally, after passing through the collecting ducts, the urine empties into the 
urinary bladder via the ureter.
Evolution
The evolution of the nephron is very illustrative for its function and starts 
content, and hence the same osmotic pressure, as the sea water in which 
compromising their internal milieu. Excretion of waste products was an 
channels in their skin. When the early vertebrates moved to fresh water, it was 
necessary to include a water impermeable layer in these channels to prevent 
dilution by the hypo-osmotic environment. This is where the glomerulus 
that was taken up. In addition, it became essential to retain salts in this fresh 
water environment. To that end a proximal tubule developed, that could 
reabsorb salt. Since this tubule is water permeable, this provides a system 
produce diluted hypotonic urine, the distal tubule was formed, where salt 
could excrete its excess water while not losing salts. Millions of years later 
the vertebrates moved to land. In this environment, conservation of salts 
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were limited to iso-osmotic reabsorption, this was not possible. Therefore 
glomeruli developed with a smaller capillary tuft to decrease the amount of 
mammals, a system developed that made concentration of urine possible, the 
so-called countercurrent exchange. The mammalian nephron contains a loop 
of Henle, that enables mammals to produce urine that is more concentrated 
than blood. The longer the loop of Henle, the more concentrated the urine 
can be20,25.
Nephrogenesis
Mammalian kidney development proceeds through three stages, the 
pronephros, the mesonephros and the metanephros, that are roughly 
characterized by mesenchymal-to-epithelial transition of intermediate 
mesoderm cells26,27. The pronephros arises in the cervical region of the 
embryo at day 22 of gestation and consists of a few tubular structures that 
are joined with the pronephric duct28,29
also seen, but they are not connected to tubules yet, making it a nonintegrated 
nephron30. The pronephric duct then extends caudally and degenerates 
rostrally with the associated pronephric kidney. At day 24 of gestation, the 
in the intermediate mesoderm have migrated caudally and now forms the 
mesonephros. The mesonephric kidney includes about 30 tubules connected 
vasculature in glomerulogenesis is uncertain. It has been described to be 
derived from resident endothelial cells31, as well as derived de novo32. In other 
words, it can be the result of angiogenesis or vasculogenesis respectively. 
Vasculogenesis refers to the de novo differentiation and association of cells into 
blood vessels, when there is no pre-existing capillary network. Angiogenesis 
involves the formation of new capillaries by sprouting, growth and remodeling 
of endothelial cells from a pre-existing vascular network33,34. On day 28 of 
extends into the caudal region of the intermediate mesoderm (metanephric 
mesenchyme, Figure 5A). After invading this mesenchymal tissue, the ureteric 
bud induces the mesenchymal cells that surround it to condense to form a 
cap35 (Figure 5B). The stroma develops around this mesenchyme and also in 
between the ureteric branches. This condensate then induces the ureteric bud 
to branch (Figure 5C) as those branches will eventually form the collecting-
duct system.  The condensate also forms pretubular aggregates that undergo 
a mesenchymal-to-epithelial transition and proliferate to form an epithelial 
1
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Figure 5. Morphological stages of early kidney development and some of the genes 
involved in its development.
(A), the  kidney starts to develop when the ureteric bud forms at the caudal end of the 
and (B), induces the mesenchyme that is adjacent to the tips of the ureteric bud (UB) to 
condense and form the stromal mesenchymal zone. (C), the condensed mesenchyme induces 
the ureteric bud to branch. (D), in association with ureteric branching morphogenesis, 
mesenchymal cells are induced in each epithelial-tip region and undergo a mesenchymal-
to-epithelial transformation to form the functional unit of the kidney, the nephron. (E), the 
nephron forms through comma- and S-shaped stages of development. The S-shaped body 
fuses to a branch of the ureteric tree, which goes on to join the collecting-duct system. 
Endothelial cells migrate into the assembling nephron to form the glomerulus. Bmp7, bone 
morphogenetic protein 7; Emx2, empty spiracles 2; Eya1, Eya1, eyes absent 1; Fgf7
growth factor 7; Foxc1, forkhead box C1; Foxd1, forkhead box D1; Gdnf1, glial cell-line-
derived neurotrophic factor 1; Gfra1
Gpc3, glypican-3; Hs2st, heparan sulfate 2-O- sulphotransferase 1; Pax1, paired-box gene 
1; Rara Ret, Ret proto-oncogene; Sall1, sal-like 1; Wnt, Wingless-
related; Wt1, Wilms tumour 1. Adapted from: coordinating early kidney development: lessons from gene 
targeting, S. Vaino and Y. Lin, Nature Review Genetics, 2002.
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tubule that is destined to form the nephron (Figure 5D-E). First, a tubule 
develops into a commashaped body, which then develops into an S-shaped 
body. The part of the S-shaped body closest to the ureteric bud becomes the 
distal tubule and fuses with the ureteric bud. The portion of the S-shaped 
body most distant from the ureteric bud folds and the outer cells become the 
Bowman capsule while the inner cells give rise to the podocytes. The middle 
part of the S-shaped body give rise to the proximal tubule and loop of Henle 
(Figure 5E)36. Figure 5 schematically illustrates nephrogenesis and depicts 
some of the genes involved.
It has become evident that the basis of eukaryotic complexity is a genetic 
via RNA-DNA, RNA-RNA, RNA-protein, and DNA-protein interactions. 
In higher organisms, about 97% of the transcriptional output consists of 
noncoding RNA (ncRNA) encompassing not only rRNA, tRNA, introns, 5’ 
and 3’ untranslated regions, transposable elements, and intergenic regions, but 
also long-noncoding RNAs (lnc-RNA) and microRNAs (miRNA)37
regulation at the post-transcriptional level by lnc-RNA and miRNA, but also 
alternative splicing, is increasingly recognized to be of vital importance to 
(molecular) cell biology and physiology. In this thesis we focused on the role 
of miRNAs in kidney pathophysiology.
MicroRNAs
MiRNAs are a family of small ~21 nucleotide long non-coding RNAs that 
38. 
Biogenesis
MiRNAs are derived from precursor molecules (pri-miRNAs) that are 
transcribed from independent genes by RNA polymerase II (canonical 
processing) or originating from introns of protein coding genes (mirtrons)39,40. 
Canonical pri-miRNAs are then processed in two steps, catalysed by two 
Drosha41 and Dicer42
processing the pri-miRNA into a ~70 nucleotide hairpin structure (pre-
41
protein (dsRBP). This pre-miRNA is then transported to the cytoplasm by 
43. Mirtron pri-miRNAs 
are a result of splicing and debranching and bypass the Drosha mediated 
processing step44. Pre-miRNAs are then cleaved by Dicer that yields a 
miRNA/miRNA* duplex42. 
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are processed from RNA 
polymerase II (RNAPII)-
independent genes (canonical 
processing) or from introns 
of protein-coding genes 
(mirtrons). In the canonical 
pathway, primary precursor 
(pri-miRNA) processing 
occurs in two steps, 
catalysed by two members 
of the RNase III family of 
enzymes, Drosha and Dicer, 
in co-operation with dsRNA-
processes pri-miRNA into 
an ~70-nucleotide precursor 
hairpin (pre-miRNA), which 
is exported to the cytoplasm 
by exportin 5. Pre-miRNAs 
that originate from very short 
introns (mirtrons) as a result 
of splicing and debranching 
will thereby bypass the 
both cases, cleavage by Dicer 
in the cytoplasm, assisted by 
transactivation-responsive 
(TAR) RNA-binding protein 
(TRBP), yields a ~20-bp 
miRNA/miRNA* duplex. One strand of the miRNA/miRNA* duplex (the guide strand) 
is preferentially incorporated into a RNA-induced silencing complex (RISC), whereas the 
poly(A) binding protein. Adapted from : The widespread regulation of microRNA biogenesis, function 
and decay, Krol et al, Nature Review Genetics, 2010.
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One strand of this duplex (the guide strand) is preferentially incorporated 
into a RNA induced silencing complex (RISC) and is the mature miRNA. 
interact with miRNAs45
proteins, which act as downstream effectors in the repression46. In general the 
end as compared to the miRNA* strand. The selective assembly of the mature 
from one end of the miRNA/miRNA* duplex47,48. The passenger strand is 
mostly degraded, although functional incorporation of passenger strands into 
RISCs has been reported49. The mature miRNAs that are then loaded in the 
RISC imperfectly base-pair with mostly the 3’UTR of a target gene, thereby 
affecting protein synthesis. In this base-pairing, it is essential that miRNA 
nucleotides 2-8 (the seed sequence) are complementary to its target mRNA 
sequence50,51. Figure 6 schematically illustrates miRNA biogenesis52.
Mode of action
Although some reports describe translational activation by miRNAs53,54, 
virtually all miRNAs are considered to act as inhibitors of protein synthesis. 
This synthesis is inhibited either by translation inhibition or promoting 
mRNA decay. Translation inhibiton was the explanation that dominated 
and more evidence is emerging that most inhibition of protein synthesis by 
miRNAs is due to mRNA destabilization. For example, using quantitative 
mass spectrometry and microarrays, it was determined that although some 
targets were repressed without detectable changes in mRNA levels, those 
that were more highly translationally repressed displayed detectable mRNA 
destabilization and often this was the major component of repression. In 
addition, they showed that an individual microRNA could directly repress 
of protein output55,56.  Another investigation measured mRNA abundance 
(using microarrays) and translation rate for approximately 8,000 genes after 
transfection of a microRNA. They found that changes in translation were 
detectable, but the reduction in mRNA abundance closely matched the 
reduction in protein level57. The most elegant investigation involved ribosome 
production and this was compared to simultaneously measured effects on 
mRNA abundance. For miRNA regulatory interactions, a decrease in mRNA 
levels accounts for around 84% of the decreased protein production58. These 
results suggest that destabilization of target mRNAs is the predominant reason 
1
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for reduced protein output by miRNAs. However, the exact mechanism(s) 
by which microRNAs exert their function are not well understood59. Several 
mechanisms have been described but the results from studies conducted in 
different systems have often been contradictory. The discrepancies could 
be due to technical issues or miRNAs indeed are able to function through 
several distinct mechanisms60. It has been shown though that the miRNA 
effect starts with translation inhibition at an early step, probably at translation 
initiation, which is followed by deadenylation of target mRNAs ultimately 
leading to the decay of mRNAs61.
microRNAs in the kidney
MicroRNAs are central players in regulatory mechanisms to modulate 
fundamental cellular processes such as differentiation, proliferation, 
metabolism, and pathophysiology of many diseases62. It has become apparent 
that miRNAs form an essential part of renal development, maintenance of 
renal function, and progression of kidney diseases. 
The involvement of miRNAs in renal development begins early by its 
regulation of the nephron progenitors. It has been shown that ablation 
of Dicer function within these nephron progenitors and the ureteric bud-
derived collecting duct system led to an increase in apoptosis and premature 
termination of nephrogenesis, which ultimately resulted in development of 
renal cysts63. Dicer, which is central to miRNA function, is thus critical for 
normal development of the nephrons. 
caused proteinuria soon after birth. This was followed by progression 
failure64. This blocking of miRNA function by Dicer ablation resulted in 
multiple abnormalities in the glomerulus such as podocyte foot process 
effacement, podocyte apoptosis and depletion, mesangial expansion, capillary 
dilation, and glomerulosclerosis65
in podocytes, which resulted in proteinuria and collapsing glomerulopathy66.
role. In diabetic nephropathy for instance, which occurs in half of the 
end stage renal failure67, miR-192 function has been shown to be strongly 
associated with the development of diabetic nephropathy. This is due to 
68,69, where decrease in miR-
70
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are directly related to the development of renal failure71. Tubulo-interstitial 
The miR-200 family provides another example of regulation through its 
72. Loss of expression of miRNAs from this 
phenotype of epithelial cells73.
functioning but this knowledge is far from complete. Since miRNAs are 
recognized as key players of biological processes, this asks for a more detailed 
that may ultimately lead to new therapeutic developments. 
Scope of thesis
In this thesis we have studied the role of a selection of miRNAs in different 
(patho-) physiological processes that are essential to our understanding of 
kidney homeostasis and disease progression.
In Chapter 2 we describe a role for miR-155 in the process of endothelial 
to mesenchymal transition (EndoMT). EndoMT has been proposed to be 
involved in the loss of microvascular capillaries in the pathophysiology of 
74,75. In EndoMT, endothelial cells (EC) undergo 
a mesenchymal transition associated with the dissolution of endothelial 
tight junctions, reorganization of the cytoskeleton, acquisition of invasive 
and migratory properties and the production and deposition of extracellular 
matrix76. We show that miR-155 functions as a negative regulator of RhoA 
In Chapters 3 and 4 we focused on Ischemia/reperfusion injury (IRI), which 
is a central event in clinical conditions such as acute kidney injury and organ 
transplantation. Emerging evidence suggests that the renal microvascular 
endothelium of the peritubular network is the primary site of injury in 
the pathogenesis of ischemia induced renal dysfunction77. In addition, 
microvascular destabilization initiated by the loss of EC-EC interactions 
capillary density due to microvascular rarefaction78,79. The resulting loss in 
1
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renal perfusion can further exacerbate medullary ischemia and drive the 
80. As a consequence, integrity of the 
peritubular capillary network is also a key determinant for the preservation 
of renal function. Chapter 3 focuses on the potential role of miR-126 in the 
mobilization of vasculogenic progenitor cells upon ischemia by modulating 
SDF-1 expression. Chapter 3 was focused on the effect of antagonizing miR-
126 systemically. In Chapter 4 however, we overexpressed miR-126 in the 
hematopoietic compartment and demonstrate that this provides protection 
against renal ischemia reperfusion injury by promoting vascular integrity. 
Chapter 5 
are known to cover and support capillary walls, are the major source of 
81
Chapter 6 
another role for miR-132 is discussed. During our experiments described in 
Chapter 5 we observed acute weight loss in mice that received antagomir-132. 
We therefore hypothesized that miR-132 plays a role in water reabsorption. 
In Chapter 6 we demonstrate that miR-132 regulates diuresis by altering 
Aquaporin-2 localization in collecting ducts, which is responsible for the 
reabsorption of water.
Finally, Chapters 7-9 provide a general summary of the research presented 
in this thesis and further discusses the role of miRNAs in kidney health and 
disease.
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Abstract
Endothelial to mesenchymal transition (EndoMT) has been proposed to 
be involved in the loss of microvascular capillaries in the pathophysiology 
mesenchymal transition associated with the loss of cell-cell contacts and the 
acquisition of a synthetic, contractile phenotype. Here, we sought to identify 
microRNAs (miRNAs) that could play a central role in regulating EndoMT. 
in vitro
that were differentially expressed in normoxic and hypoxic conditions. These 
effect that was enhanced under hypoxia, which further augments EndoMT.
Silencing of miR-155 directly increased RhoA expression and activity in 
endothelial cells and affected phosphorylation of downstream LIMK. 
In contrast, overexpression of miR-155 counteracted RhoA function. 
Using a selective Rho kinase inhibitor, we could partly suppress EndoMT, 
strengthening the notion that RhoA plays a central role in EndoMT. Forced 
overexpression of miR-155 completely suppressed EndoMT, as evidenced 
by the maintenance of EC characteristics and blocking the acquisition of a 
mesenchymal phenotype, as compared to control cells. Our data demonstrate 
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Introduction
Endothelial to mesenchymal transition (EndoMT) is an essential process in 
embryonic development of the heart valves and involves dedifferentiation 
of endothelial cells towards a mesenchymal, synthetic phenotype1,2. At the 
same time, evidence is accumulating that EndoMT can also contribute to the 
loss of the microvasculature in the adult, limiting the long-term survival of 
transplanted organs3 and leading to end organ failure in progressive cardiac and 
renal disease4. EndoMT involves the dissolution of endothelial tight junctions, 
reorganization of the cytoskeleton, acquisition of invasive and migratory 
properties and the production and deposition of extracellular matrix5. These 
evidence is accumulating that EndoMT provides another source of tissue 
4. A common denominator in chronic diseases associated with 
of nitric oxide (NO)6. In mice, long term inhibition of NO synthesis with 
inhibitors of endothelial nitric oxide synthase (NOS3) leads to induction of 
endothelial cells (EC)7
8. These studies strongly suggest 
9. 
to the excessive formation of scar tissue, the associated loss of microvascular 
EC and capillary density, that eventually leads to a state of chronic ischemia, 
5
in the phosphorylation of SMAD2 and SMAD3. The phosphorylated 
SMAD2/3 complex subsequently associates with SMAD4 and translocates 
to the nucleus. This complex binds to SMAD-binding DNA elements and 
also to several regulatory molecules, thereby activating various transcriptional 
networks10,11.  
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MicroRNAs (miRNAs) are small ~22 nucleotide regulatory RNAs that 
function as negative regulators of gene expression12. Since these molecules 
play a central role in regulating cellular differentiation, miRNAs may also be 
involved in EndoMT. Support for this notion can be derived from the fact 
to mesenchymal transition (EMT). Among the best characterized miRNAs, 
miR-200 has been found to regulate EMT, by targeting the transcriptional 
13. Furthermore, miR-21 has been 
shown to be upregulated in EMT14 15. 
More recently, initial evidence detailing a role for miRNAs in EndoMT has 
come to light, with miR-21 silencing phosphatase and tensin homolog in EC 
resulting in activation of the Akt-pathway16. 
embryonic endothelial cells (MEEC), and determined the miRNA expression 
miRNAs. While miR-155 is important in regulating diverse processes such as 
immune regulation and cancer17, a role for this miR in EndoMT is currently 
unknown. Ras homolog gene family, member A (RhoA), which is a well-
established target of miR-15518, has been described as a regulator of EMT. 
In this study, we demonstrated that modulation of miR-155 levels in EC can 
affect EndoMT via targeting the RhoA pathway. 
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Materials and Methods
Cell Culture and induction of EndoMT
described19. MEEC were maintained on 1% (w/v) gelatin coating in Dulbecco’s 
supplemented with 10% fetal calf serum and 2 mM L-glutamine (Invitrogen). 
hours, unless indicated otherwise. For the culture of MEEC under hypoxic 
levels of <1%. To effectively block RhoA activity, we used the Rho kinase 
concentration of 3.5 μg/mL. For the scratch assay, MEEC were scraped in 
a straight line with a 200 μL pipette tip. A reference point was marked with 
a tip marker. Cell migration after 24 hours of incubation was determined by 
microscopy and expressed as migration distance in μm. 
MiRNA microarray
microarrays V2 (Invitrogen). For this, isolated RNA was poly-A tailed, 
followed by ligation of the capture sequences. Subsequently, the tagged 
labeled capture reagents were hybridized and signal intensity measured 
using an array reader. Data analysis was performed using BRB-ArrayTools 
developed by Dr. Richard Simon and BRB-ArrayTools Development Team. 
All data were normalized to miR-125b, as we have previously found miR-
RNA isolation and qRT-PCR analysis
Total RNA from kidneys was isolated using Trizol reagent (Invitrogen). 
Reverse transcription was performed using a 5 minute 65ºC incubation 
of 250 ng total RNA with dNTPs (Invitrogen) and oligo(dT) (Invitrogen) 
Foster City, CA, USA). cDNA was synthesized using a M-MLV First-
Strand Synthesis system (Invitrogen). Validation of target genes was 
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Biosystems) according to manufacturer’s instructions (Invitrogen),RNU6B 
using the delta delta Ct method.
Western Blot
Western blot analyses were performed on cellular lysates harvested in lysis 
buffer (50 mM Tris-HCl pH7.5, 150 mM NaCl, 1% SDS, 0,5% deoxycholate, 
0,5% Triton X-100) containing phosphatase and protease inhibitors. 
Following quantitation of protein determination, equal amounts of proteins 
conditions. Proteins were transferred to a PVDF membrane (Amersham, ‘s 
Hertogenbosch, the Netherlands). Primary antibodies were utilized to detect 
Co, USA).  Bound primary antibody was labeled with HRP-conjugated 
secondary antibody in blocking solution. Bound fragments were detected 
with chemiluminescent reagents (West Dura supersignal; ThermoFisher 
.
Antagonism and overexpression of miR-155
Design of Antagomirs
Cholesterol-conjugated RNA analogs, ‘antagomirs’, (Dharmacon RNA 
technologies, Lafayette, CO, USA) were synthesized as previously 
described20. For antagomir-155 the following sequence was used: 5’- 
ascscccuaucacaauuagcaususasas-Chol-3’. As a control a ‘scramblemir’ was used, 
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this RNA analog is constructed from a randomized nucleotide sequence which 
does not bind to any known microRNAs: 5’-asusgacuaucgcuauucgcsasusgs-
Chol-3’. The lower case letters represent 2’-O
subscript ‘s’ represents phosphorothiate linkage; ‘Chol’ represents a 
cholesterol-group linked through a hydroxyprolinol linkage. Antagomir 
stimulation at a concentration of 5 μg/mL.
Overexpression of miR-155
To overexpress miR-155, a synthetic pre-miR-155 precursor (Applied 
concentration of 100 nM. As a control, we used a negative control precursor 
molecule.  Per well, 4 μL of Lipofectamine 2000 (Invitrogen) was added to 
facilitate transfection.
Immunocytochemistry
For immunocytochemistry, MEEC were seeded into 4-well chamber slides. 
with 4% paraformaldehyde at room temperature for 5 min. The cells were 
subsequently washed again, and permeabilized with 0.5% Triton X-100 in 
PBS for 5 min at room temperature. Cells were then blocked with 10% 
normal goat serum in PBS for 30 min at room temperature, and incubated for 
1 hr with primary antibodies. The following primary antibodies were used: 
F-actin was visualized with 2 μg/mL phalloidin-TRITC (Sigma-Aldrich), 
pLIMK1/pLIMK2 (Cell Signaling Technology, Leiden, the Netherlands), 
1 hour at room temperature with the appropriate secondary antibodies. The 
4’,6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, Burlingame, 
(Leica DM1-6000).
RhoA activity assay
performed according to the protocol of the manufacturer.
Statistical Analysis
Results are expressed as mean ± standard error of the mean (SEM). Statistical 
analysis was performed using Student’s t-test. P<0.05 was considered 
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Results
in vitro and 
assessed whether they displayed mesenchymal characteristics. When MEEC 
(Figure 1A-B). A hallmark feature of mesenchymal transition is the expression 
contraction. When we visualized F-actin by immunostaining with phalloidin 
 A-B, Representative microscopic images of 
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21 (Figure 
regulated as previously described in EMT22. In contrast, the expression of 
EC intercellular junction protein CD31 was decreased.  Western blot analysis 
the level of protein expression (Figure 1H).  
EndoMT in vivo5, we investigated whether hypoxia also augmented EndoMT 
in MEEC. MEEC were cultured under normoxic and hypoxic conditions 
expectation, hypoxia induced a cellular disorganization that, when combined 
in F-actin immunostaining, as evidenced by a highly disorganized staining 
Finally, to validate increased production and deposition of extracellular 
matrix (ECM) under conditions of hypoxia, we performed Sirius Red staining 
production that was even furthers pronounced in hypoxia (from 4.51 ± 0.20 
of these cells to study mechanisms in EndoMT. 
To identify miRNAs that are differentially expressed during EndoMT, 
unstimulated control cells and processed the samples to determine their 
427 miRNAs assessed, 62 miRNAs displayed differential expression during 
the dedifferentiation process, while 11 miRNAs were upregulated during 
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expression for all tested miRNAs (Table 1). 
In our search for miRNAs that regulate EndoMT we selected miR-155 for 
further study as this miRNA is was one of the few up regulated miRNAs and 
18. 
Figure 2. Hypoxia augments, and RhoA is essential for, EndoMT.
A-B, representative microscopic images of cells cultured under hypoxic conditions in the 
of F-actin. E-H, Rho/ROCK inhibitor Y-27632 suppresses EndoMT. Representative 
Expression is relative to cell number. K, qRT-PCR analysis shows that miR-155 expression 
is increased in EndoMT and augmented by hypoxia. L, qRT-PCR analysis shows reduced 
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155 levels both under normoxic and hypoxic conditions in the presence or 
on miR-155 expression levels and that miR-155 expression quantitatively 
follows EndoMT.
Rho/Rock inhibition partly inhibits EndoMT
whether there is also a role for RhoA in EndoMT in MEEC. Using the Rho 
EndoMT as indicated by a preservation of endothelial cell morphology (Figure 
 
Data is normalized on miR-125b expression, which is the most highly expressed miRNA in 
as compared to miR-125b expression level. Third and fourth column show differential 
expression as determined by respectively microarray and qPCR. – is downregulation, + is 
upregulation.
miRNA TGF- Fold Change
- + array qRT -PCR
miR -125b 1 1 1 1
miR -424 0.13 0.03 -4.3 -2.5
miR -696 0.51 0.21 -2.4 1
miR -93 0.21 0.09 -2.3 n/a
miR -130a 0.19 0.09 -2.0 n/a
miR -15a 0.13 0.07 -1.9 n/a
miR -15b 0.13 0.07 -1.9 n/a
miR -106b 0.16 0.09 -1.8 n/a
miR -22 1 0.14 0.08 -1.8 n/a
miR -20a 0.13 0.08 -1.6 n/a
miR -16 0.34 0.21 -1.6 -2.0
miR -31 0.26 0.18 -1.4 n/a
miR -29a 0.31 0.22 -1.4 -1.5
miR -214 0.06 0.09 +1.5 +2.8
miR -155 0.06 0.08 +1.3 +1.5
miR -199a 0.08 0.10 +1.3 +2.0
miR -199a* 0.09 0.12 +1.3 +2.0
miR -22 0.17 0.22 +1.3 +1.5
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2L). This indicates that RhoA is essential for full transition of endothelial 
cells towards a mesenchymal phenotype.
silence miRNA expression in EC both in vitro as well as in vivo23. To study the 
effect of miR-155 silencing during EndoMT, we employed an antagomir to 
miR-155 and a control scramblemir that was designed to lack complementary 
to the mouse transcriptome. When we assessed the effect of silencing of 
Figure 3. Effect of miR-155 silencing on EndoMT and RhoA signaling. 
MEEC. C, Western blot for RhoA. Antagomir-155 vs scramblemir control at baseline and 
cells. E, increased migratory capacity of MEEC as a result of miR-155 silencing. Migration 
distance in μm was measured in a scratch assay.
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miR-155 on markers of EndoMT 48 hours after treatment we observed 
0.3, p<0.05) suggesting a repressive role for miR-155 in the basal regulation 
of cytoskeletal organization. 
MiR-155 regulates RhoA expression and activity in MEEC 
24 
we sought to determine if, similar to what has been described for EMT, miR-
155 can also regulate RhoA in EndoMT. Since the conversion of RhoA to 
25
stimulation in antagomir-155 and scramblemir treated cells. Figure 3B shows 
activity of RhoA activity in MEEC both before and at 1 and 2.5 hr after 
 demonstrated that silencing of 
miR-155 increases RhoA protein expression concomitant to the increased 
exceed the silencing effect of antagomir-155.  To further support the effect 
of miR-155 silencing on RhoA activity we assessed the phosphorylation of 
LIM kinase (pLIMK), a downstream effector of RhoA dependent stress 
24
antagomir-155 or scramblemir and stained for pLIMK at baseline and after 
a negative role for miR-155 in RhoA signaling. RhoA has been described to 
regulate the migration in endothelial cells26. We performed a scratch assay 
to see if cell migration was also affected by the silencing of mir-155. Twenty 
four hours after making a scratch, we found that the loss of miR-155 activity 
has a stimulatory effect on Rho-A dependent migration both in unstimulated 
limiting role for miR-155 in RhoA activity in MEEC.
EndoMT 
Following the above we postulated that overexpression of miR-155 could 
counteract EndoMT in MEEC. To test this hypothesis we treated MEEC for 
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for 48 hr to induce EndoMT. Increased levels of miR-155 lead to a virtually 
the maintenance of EC morphology (Figure 4A), while Western blot analysis 
of lysates harvested from MEEC treated with pre-miR-155 revealed that 
the regulatory role of miR-155 on EndoMT is secondary to inhibition of 
RhoA expression we also determined RhoA expression at baseline and 1 
miR-155 reduces RhoA protein levels compared to the scrambled control 
pre-miR (Figure 4C). Finally, overexpression of miR-155 was associated with 
Figure 4. miR-155 overexpression inhibits EndoMT.
control. C, RhoA Western blot, pre-miR-155 versus control pre-miR at baseline and 1 hr 
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Discussion
In this study, 
to mesenchymal transition and that this mechanism involved the activation 
prominent and an increase in production of extracellular matrix is found. 
When MEEC are cultured under hypoxic conditions, these features are even 
stronger.
and found several differentially regulated miRNAs. Overall, we found more 
effect on miRNA biosynthesis. This could be true as it has been described 
27. 
Several papers described endothelial cells to contribute to the development 
28,29. The 
pericyte-like cells30. This could mean that the processes of EMT and 
EndoMT. Furthermore, it is generally accepted that EndoMT is important in 
embryogenesis, e.g. during formation of the heart.
  
through targeting RhoA. We found the effect on RhoA activity and expression 
presence of antagomir-155, and vice versa when miR-155 was over expressed, 
effects were observed. In addition, in retinal epithelial cells it is described 
expression that way31
RhoA, thereby inducing endothelial barrier dysfunction32. By overexpressing 
   
In concordance with upregulation of RhoA activity due to silencing of miR-
155 we found increased expression of phosphorylated LIM-kinase, which is 
phosphorylated by ROCK, the direct target of RhoA24. pLIMK in its turn 
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activity anymore. So antagomiR-155 contributes to Rho-induced 
reorganization of the actin cytoskeleton and provides further evidence that 
miR-155 modulates EndoMT through RhoA regulation. Based on our data 
and supportive literature we propose a mechanism as illustrated in Figure 5.
Nevertheless, it is very well possible that miR-155 functions through other 
targets as well. For example, it has been described that miR-155 targets 
33. This mechanism 
could also be important in the context of EndoMT as SMAD5 could be 
includes SMAD234
During this transition miR-155 expression is increased, and is shown to 
modulate RhoA, and thereby acts as a negative feedback regulator. We 
showed that over expression of miR-155 can completely inhibit EndoMT 
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Figure 5. Schematic illustration of miR-155 
function in EndoMT. 
dependent manner. In addition, hypoxia 
other EndoMT related genes. RhoA is suppressed 
by miR-155, which implies a negative feedback role 
for miR-155 in RhoA regulation, and therefore 
EndoMT.




2. Nakajima, Y., Yamagishi, T., Hokari, S. & Nakamura, H. Mechanisms involved in valvulosep-
tal endocardial cushion formation in early cardiogenesis: roles of  transforming growth factor 
3. Bruneau, S., et al. Key Features of  the Intragraft Microenvironment that Determine Long-Term 




ers of  endothelial activation in kidney disease. Nat Rev Nephrol 6, 404-414 (2010).
7. O’Riordan, E., et al. Chronic NOS inhibition actuates endothelial-mesenchymal transforma-
Med 13, 952-961 (2007).
the rat. Cardiovasc Res 26, 671-677 (1992).
5764-5774 (2005).
-
ment and disease. Nat Rev Mol Cell Biol 8, 857-869 (2007).
12. Filipowicz, W., Bhattacharyya, S.N. & Sonenberg, N. Mechanisms of  post-transcriptional regu-
mesenchymal transition. Cell Cycle 7, 3112-3118 (2008).
and microRNA:mRNA regulatory networks in epithelial plasticity. Cells Tissues Organs 185, 
157-161 (2007).
15. Thum, T., et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase 
16. Kumarswamy, R., et al. Transforming growth factor-beta-induced endothelial-to-mesenchymal 
transition is partly mediated by microRNA-21. Arterioscler Thromb Vasc Biol 32, 361-369 
(2012).
-
cer. Int Rev Immunol 28, 264-284 (2009).
18. Kong, W., et al. MicroRNA-155 is regulated by the transforming growth factor beta/Smad 
pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol 28, 6773-
6784 (2008).
(2005).
46   
-
tastasis. Cell 117, 927-939 (2004).
22. Taki, M., et al. Up-regulation of  stromal cell-derived factor-1alpha and its receptor CXCR4 
expression accompanied with epithelial-mesenchymal transition in human oral squamous cell 
carcinoma. Oncol Rep 19, 993-998 (2008).
24. Maekawa, M., et al. Signaling from Rho to the actin cytoskeleton through protein kinases 
ROCK and LIM-kinase. Science 285, 895-898 (1999).
25. Bhowmick, N.A., et al. Transforming growth factor-beta1 mediates epithelial to mesenchymal 
transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell 12, 27-36 (2001).
angiogenesis in vitro. Oncol Rep 15, 1147-1152 (2006).
microRNA maturation. Nature 454, 56-61 (2008).
(2008).
-
Pathol 175, 1380-1388 (2009).
-
gene and effector that regulates alpha-smooth muscle actin expression and cell migration. Mol 
Biol Cell 21, 860-870 (2010).
-
375-384 (2006).
33. Rai, D., Kim, S.W., McKeller, M.R., Dahia, P.L. & Aguiar, R.C. Targeting of  SMAD5 links mi-
3111-3116 (2010).
285, 41328-41336 (2010).
miR-155 regulates EndoMT through RhoA    47
2

         Chapter
MicroRNA-126 modulates endothelial 
SDF-1 expression and mobilization of Sca-1+/Lin- 
progenitor cells in ischemia
3
Cardiovasc Res. 2011 Dec 1;92(3):449-55.
Coen van Solingen1,2, Hetty C. de Boer1,2, Roel Bijkerk1,2, Matthieu Monge1, Annemarie 
M. van Oeveren-Rietdijk1,2, Leonard Seghers2,3, Margreet R. de Vries2,3, Eric P. van der 
Veer1,2 2,3 1,2 1,2
1Department of Nephrology and the 2Einthoven Laboratory for Experimental Vascular 
Medicine, 3Department of Surgery, LUMC, Leiden, the Netherlands.
50  
Abstract
MicroRNA-126 (miR-126), which is enriched in endothelial cells, plays a role 
in angiogenesis. Based on the seed sequence, miR-126 can also be predicted 
to regulate vasculogenesis by modulating the endothelial expression of 
stromal cell-derived factor-1 (SDF-1). Using miR-reporter constructs, we 
in vitro. Next, we investigated the potential relevance of this observation 
with respect to the mobilization of progenitor cells. For this, we studied the 
migration of human CD34+ progenitor cells towards chemotactic factors 
present in endothelial cell-conditioned medium. Antagomir-induced silencing 
of miR-126 elevated SDF-1 expression by human umbilical vein endothelial 
cells and enhanced migration of the CD34+ cells. In a murine model of hind 
limb ischemia, a striking increase in the number of circulating Sca-1+/Lin- 
progenitor cells in antagomir-126-treated mice was observed as compared to 
scramblemir-treated controls. Immunohistochemical staining of capillaries in 
the post-ischemic gastrocnemius muscle of miR-126-silenced mice revealed 
elevated SDF-1 expressing CD31-positive capillaries, whereas a mobilizing 
effect of miR-126 inhibition was not detected in healthy control animals. 
MiR-126 can regulate the expression of SDF-1 in endothelial cells. In the 
context of an ischemic event, systemic silencing of miR-126 leads to the 
mobilization of Sca-1+/Lin- progenitor cells into the peripheral circulation, 
potentially in response to elevated SDF-1 expression by endothelial cells 
present in the ischemic tissue. 
   51
3
Introduction
Integrity of the vascular endothelium is central to vascular homeostasis and 
is determined by the balance between endothelial injury and repair1. In the 
context of adverse hemodynamic and metabolic risk factors, endothelial cells 
(ECs) are damaged and constantly replaced by the proliferation of adjacent 
mature ECs. In the rat aorta, ECs in areas resistant to atherosclerosis have 
a low rate of cellular replication and have been estimated to have a lifespan 
of approximately 12 months. In contrast, EC turnover in lesion-prone sites 
is accelerated to weeks or less as animals age2. To maintain the integrity of 
the endothelium throughout life, endothelial cells in the arterial wall would 
therefore have to replicate well over a thousand times. However, primary 
endothelial cell cultures already become senescent after a limited number 
of passages due to a progressive shortening of telomeres that takes place 
upon each cell division. Moreover, telomere erosion is accelerated by chronic 
exposure of endothelial cells to oxidative stress3. Consequently, it has 
chronically damaged endothelium throughout life. Support for this notion 
by endothelial progenitor cells as an alternative cellular source for re-
endothelialization of the damaged artery wall4-6. 
Stromal cell derived factor-1 (SDF-1 or CXCL12) has been demonstrated 
to facilitate the homing of progenitor cells from the peripheral circulation 
to sites of vascular injury or tissue ischemia. SDF-1 can be actively secreted 
by injured endothelial cells7 or activated platelets8, leading to the homing of 
bone marrow-mobilized progenitor cells to the site of injury9,10
role of SDF-1 in recruiting bone marrow cells to ischemic tissue has been 
established in several animal models to improve recovery after an ischemic 
event7,11-13. Therefore, SDF-1 is believed to play a central role in regulating 
both vascular integrity and homeostasis, implicating that its expression should 
be tightly controlled. Indeed SDF-1 expression is reported to be regulated at 
multiple levels including transcription and post-translation7. 
At the post-transcriptional level, SDF-1 expression could be regulated by 
microRNAs (miRNAs). MiRNAs constitute a class of highly conserved non-
coding RNAs that control gene expression by inhibiting the translation of 
mRNA14. The ability of miRNAs to regulate multiple targets provides a means 
for the coordinated control of gene expression and make these molecules 
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and modulating cell function15
of ECs have been analyzed in detail and recent studies demonstrated both 
pro-angiogenic16-19 as well as anti-angiogenic functions for endothelial 
miRNAs20,21. 
In silico analyses (http://www.microrna.org) for miRNAs targeting the 3’ 
potential post transcriptional regulator of SDF-1 expression. MiR-126 is highly 
enriched in ECs and has been demonstrated to regulate (ischemia-induced) 
angiogenesis by blocking the expression of SPRED-1 and PI3KR222-24. Here, 
we validated the inhibitory actions of miR-126 on expression and function of 
SDF-1 in ECs in vitro. Furthermore, we demonstrate that antagomir-induced 
silencing of miR-126 prior to acute ischemia leads to the augmentation of 
SDF-1 levels in both the circulation and ischemic tissue. This is associated 
with increased mobilization of bone marrow-derived progenitor cells in vivo. 
Our data demonstrate that endothelial miR-126 can regulate both features of 
angiogenesis as well as vasculogenesis and suggest a role for miR-126 in the 
maintenance of endothelial homeostasis.  
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Materials and Methods
Cells and Cell Culture
Immortalized human umbilical vein endothelial cells (EC-RF24)25 were 
(FCS, Bio Whittaker/Cambrex, Verviers, Belgium), 10 IU/mL heparin (Leo 
Human umbilical vein endothelial cells (HUVEC) were isolated, cultured 
and characterized as described previously26. In short, ECs were isolated 
from freshly obtained human umbilical cords by trypsin/EDTA digestion 
of the interior of the umbilical vein. The cells were cultured in M199 
medium supplemented with penicillin/streptomycin, 20% FCS, 10 IU/mL 
+ cells were isolated 
from umbilical cord blood using Ficoll (Amersham, ‘s-Hertogenbosch, the 
Netherlands) density gradient centrifugation and positive selection using 
from the university ethics review board was not necessary.
SDF-1 3’UTR Reporter Assays
Synthetic, double-stranded oligonucleotides spanning a 60 base-pair region of 
the murine 3’UTR of SDF-1 mRNA containing the putative miR-126 binding 
the seed-sequence were cloned into the pMIR-reportTM Expression Reporter 
Vector System (Applied Biosystems, Amsterdam, the Netherlands; see online 
publication for oligonucleotide sequences). All plasmids were sequenced to 
 
expression plasmid (pRL-SV40, Promega, Leiden, the Netherlands) and a 
plasmid containing a single, perfect match miR-126 binding site served as 
controls23. 
Design of Antagomirs
Antagomir-126 and a control scramblemir (Dharmacon RNA technologies, 
Lafayette, CO) were synthesized as previously described23. 
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Luciferase Assay
after antagomir treatment, the EC-RF24 cells were detached by trypsinization 
cell suspension was chilled for 10 minutes at 4ºC and electroporated using 
After 10 minutes recovery time at room temperature, 1.5x10E5 cells were 
Western Blot
scramblemir. Culture medium was aspirated and cells were washed two 
times with PBS, cellular lysates were harvested using lysis buffer (50 mM 
Tris-HCl (pH=7.5), 150 mM NaCl, 1% SDS, 0.5% sodiumdeoxycholate and 
were assessed by Western blot analysis with chemiluminescence detection. 
Equal amounts of protein were resolved on 15% SDS-polyacrylamide gels 
and transferred to PVDF membranes (Millipore, Billerica, MA). SDF-1 was 
detected using a polyclonal rabbit antibody against human SDF-1 (0.5 ug/
the Netherlands) was used as secondary antibody. Bound fragments were 
detected with chemiluminescent reagents (Supersignal West Dura Extended 
antagomir-126 treated HUVEC was arbitrarily set at 100%.
Migration Assay
insulin-transferrin-sodium selenite media supplement (ITS, Sigma-Aldrich) 
cell supernatants were harvested and placed into the lower compartment of 
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Amsterdam, the Netherlands). Human CD34+ cells were added to the upper 
chamber and migration was followed over a period of 4 hours at 37ºC. As 
a positive control 50 ng/mL recombinant human SDF-1(R&D Systems) 
was added in the lower compartment. The SDF-1-receptor, CXCR4, was 
neutralized by incubation of CD34+ cells with a blocking antibody against 
cell-suspensions in the lower compartment were harvested, spun down and 
incubated for 30 minutes at 4ºC in FACS buffer (PBS + 1% bovine serum 
albumin (BSA, Sigma-Aldrich)) with directly conjugated antibodies against 
human CD34 (PerCP-Cy5, BD Biosciences, Breda, the Netherlands) and 
+ cells 
Minneapolis, MD) and added prior to FACS analysis. 
Hind Limb Ischemia Model
All animal experimental protocols were approved by the animal welfare 
(TNO, Leiden, the Netherlands) and conform the Directive 2010/63/
EU of the European Parliament.One day prior to surgery, C57BL/6 
WT mice (n=6 per group, age=10 weeks, Charles River, Maastricht, the 
mg/animal) or scramblemir (1.0 mg/animal). Before surgery, mice were 
anesthetized intraperitoneally with a combination of Midazolam (5 mg/
kg, Roche Diagnostics, Almere, the Netherlands), Medetomidine (0.5 mg/
Pharmaceutica, Tilburg, the Netherlands). Ischemia of the left hind limb was 
induced by electrocoagulation of the left common femoral artery, proximal 
27. To 
coagulated) by heart puncture and the tibia and femur of both legs were kept 
for isolation of bone marrow cells. Additionally, the gastrocnemius muscle 
of both hind limbs was dissected and placed in 4% formaldehyde overnight. 
immunohistochemical analysis. 
Whole Blood Analysis
Whole blood was collected by incision of the tail vein or heart puncture and 
analyzed by semi-automatic hematology analyzer F-820 (Sysmex; Sysmex 
Corporation, Etten-Leur, the Netherlands), FACS-analysis or ELISA. 
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Hematological values obtained were white blood cell counts (WBC, n*106/
mL), red blood cell counts (RBC, n*109/mL), platelets (PLT, n*106/mL), 
conjugated antibodies directed against Sca-1 (FITC, BD-Biosciences), Flk-1 
(PE, BD-Pharmingen, San Diego, CA) and a cocktail against lineage-positive 
incubated with an appropriate cocktail of isotype controls, to identify the 
threshold for lineage-positivity. SDF-1 levels in serum were assessed with 
ELISA (R&D Systems). 
Immunohistochemistry 
and incubated with antigen-retrieval buffer (0.1% trypsin/EDTA in PBS). 
FACS Analysis
All samples obtained for FACS analysis were either immediately analyzed by 
paraformaldehyde and analyzed within 24 hours after preparation. Data were 
analyzed using FACSDiVa software (BD Biosciences).
Statistical Analysis
Results are expressed as mean ± standard error of the mean (SEM). Statistical 
analysis was performed using the Mann-Whitney T-test. P<0.05 was 
   57
3
Results
MiR-126 affects the expression and function of SDF-1 in vitro
Using an on line miRNA target search tool (http:// www.microrna.org) we 
To assess its functionality, we cloned this binding site into the 3’UTR of a 
luciferase reporter gene driven by a constitutive promoter (pSDF) and analyzed 
luciferase expression and of a control plasmid in the human endothelial cell 
line EC-RF24. In these miR-126 expressing cells, luciferase expression driven 
from a reporter construct lacking a miRNA seed sequence (pMIR) was not 
affected when miR-126 was silenced using an antagomir approach (anta-126). 
In contrast, a reporter gene carrying a single perfect miR-126 binding site 
(pMONO) was fully active when miR-126 was silenced but its expression was 
Figure 1. MiR-126 affects the 
expression and function of 
SDF-1 in vitro.
A, EC-RF24 were pre-
incubated with scramblemir or 
antagomir-126 and transfected 
with pMIR as negative control, 
pMONO as positive control, 
pSDF with the sequence of the 
SDF-1 miR-126 binding site or a 
variant with a single mismatch in 
the seed sequence (pSDFmm). 
Experiments were performed in 
triplicate and data are expressed 
as mean values ± standard error 
of the mean. B, HUVEC were 
incubated for 48 hours with 
antagomir-126 or scramblemir 
and conditioned cell supernatants 
subjected to Western blot analysis 
for SDF-1. C, HUVEC (n=4) 
were treated with antagomir-126, 
scramblemir or vehicle and the 
conditioned media were used to 
study the chemotactic activity 
towards human hematopoietic CD34+ cells in vitro. Recombinant SDF-1 was used as 
positive control and the contribution of the SDF-1 receptor (CXCR4) was studied with the 
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strongly reduced in the presence of a control scramblemir (scr). These studies 
of the putative SDF-1 miR-126 binding site in the reporter construct led to 
a 40% reduction of luciferase-expression in miR-126 expressing cells (Figure 
1A, scramble vs. antagomir-126, P<0.01). A single mismatch in the seed 
of the seed sequence, pSDFmm) alleviated miR-126-dependent repression of 
126 binding site in the 3’UTR of the SDF-1 mRNA. To validate the regulatory 
effect of miR-126 on endogenous SDF-1 protein expression in endothelial 
cells, human umbilical vein endothelial cells (HUVEC) were treated with 
antagomir-126 or scramblemir, after which SDF-1-protein expression was 
determined by Western blot analysis. A marked increase of SDF-1 protein 
expression was observed in HUVEC treated with antagomir-126 as compared 
to scramblemir (Figure 1B). 
Next, we assessed the potential of miR-126 to regulate the extent by 
which endothelial cell-derived SDF-1 attracts progenitor cells. To this end, 
conditioned medium derived from HUVEC, incubated with antagomir-126 
or scramblemir, was applied to the lower compartment of a transwell-system 
and umbilical cord blood-derived CD34+ cells were placed in the upper 
compartment. As shown in Figure 1C, silencing of miR-126 in HUVEC-
enhanced migration of CD34+ cells compared to the scramblemir-control 
(P<0.001). Moreover, neutralization of CXCR4 expressed by the CD34+ 
migration towards the conditioned supernatant derived from antagomir-126 
treated HUVEC back to the scramble control levels (P<0.05). As a 
control, maximal cellular migration was observed using medium containing 
126 in endothelial cells in vitro can augment expression of functional SDF-1, 
leading to elevated progenitor cell migration.
MiR-126 affects progenitor cell mobilization via SDF-1 in vivo
Endothelial miR-126 expression and functionality is conserved in murine 
EC, both in vivo23 and in vitro (data not shown). To investigate the regulatory 
role of miR-126 on SDF-1-dependent progenitor cell mobilization in vivo, we 
applied single tail vein injections of antagomir-126 or the control scramblemir 
into wild type (WT) male C57Bl/6 mice (n=6) Ten days after injection, we 
enumerated the number of circulating Sca-1-positive and lineage-negative 
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(Sca-1+/Lin-) cells by FACS analysis. Surprisingly, when we expressed the 
circulating Sca-1+/Lin- cell numbers as a percentage of Lin+ leukocytes, we 
+/Lin- cells in the mice 
in which miR-126 had been silenced by antagomir-126 administration as 
compared to the scramblemir-treated controls (Figure 2A, P<0.05). This 
observation could be explained by the fact that antagomir-126 treated mice 
(Figure 2B, P<0.01). Such an increase is consistent with reports showing that 
increased SDF-1 levels in the circulation result in an elevation of WBCs9. 
As such, when we expressed the number of circulating Sca-1+/Lin- cells per 
mL blood, the differences between antagomir-126 and scramblemir-treated 
animals was lost, indicating that there is no systemic role for miR-126 in Sca-
1+/Lin- progenitor cell mobilization in vivo (Figure 2C). 
Ischemic endothelial cells have been established to up regulate SDF-17, 
shown). We investigated whether an ischemic stimulus in combination with 
attenuation of miR-126 levels would modulate progenitor cell levels in mice. 
Therefore, we injected male WT mice (n=6) with either antagomir-126 or 
scramblemir and, the next day, this procedure was followed by the induction 
of unilateral hind limb ischemia (HLI). Ten days after induction of HLI, the 
Although systemic SDF-1 levels were elevated in antagomir-126-treated mice 
Figure 2. MiR-126 does not solely affect mobilization of Sca-1+/Lin- cells in vivo. 
A, Ten days after injection of scramblemir or antagomir-126, Sca-1+/Lin- cells in whole 
blood were analyzed by FACS, expressed as percentage of total Lin+ leukocytes. B, Ten days 
after injection of scramblemir or antagomir-126, total white blood cell counts per mL was 
determined. C, Ten days after scramblemir- or antagomir-126-injection Sca-1+/Lin- cells 
were analyzed by FACS in whole blood expressed as total number in mL blood.
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Nevertheless, when we examined the in vivo mobilization of Sca-1+/Lin- cells 
to the circulation after ischemia, we observed an 8-fold increase of Sca-1+/
Lin- cells expressed as percentage of total Lin+ leukocytes in the blood of 
Figure 3. MiR-126 can alter SDF-1-expression and induce progenitor mobilization 
after ischemic injury in vivo. A, Ten days after HLI antagomir-126-treated mice showed 
controls (n=6). B, Ten days after HLI and injection of scramblemir or antagomir-126, 
Sca-1+/Lin- cells were measured in whole blood, expressed as percentage of total Lin+ 
leukocytes C, Immunohistochemical micrographs of immunohistochemistry of the 
gastrocnemius muscle after HLI showed colocalization of SDF-1 and CD31. SDF-1 was 
visualized with alexa-488 (green) and CD31 with alexa-568 (red). Nuclei were stained 
with DAPI and shown in blue, Nomarsky contrast images show muscle tissue. Scale bars 
treated mice have increased levels of SDF-1 positive capillaries as percentage of total 
number of capillaries (n=6). 
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antagomir-126-treated animals as compared to scramblemir-treated control 
animals (Figure 3B, P<0.005). The absolute number of Sca-1+/Lin- cells per 
mL blood was raised from 0.24 ± 1.4 in the control group to 2.1 ± 1.4 in the 
antagomir-126 treated animals. As the observed effects suggested an ischemia-
dependent elevation of SDF-1, we next investigated whether the ischemic 
gastrocnemius muscle could be a potential contributor to the elevated levels 
of circulating SDF-1. Therefore, we performed both detailed qualitative and 
quantitative immunohistochemical analysis of SDF-1 expression in relation 
to CD31-positive capillaries. Indeed, we observed a clear co-localization of 
SDF-1 and CD31 expression in sections of the ischemic muscle (Figure 3D). 
Furthermore, the ischemic muscle of antagomir-126-treated animals showed 
a higher percentage of double-positive capillaries (Figure 3C, P<0.01) as 
opposed to scramblemir-treated controls. These data imply that the mildly 
elevated levels of SDF-1 protein in the circulation upon antagomir-126-
protein in the vessels of ischemic tissue. 
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Discussion
A function for miR-126 in angiogenic processes in vascular maintenance 
and during development has been shown in a number of publications 
demonstrating that loss of miR-126, either in knockout models or mediated 
by treatment with antagomirs, leads to structural impairment of the vascular 
bed22-24. In the current study, we provide evidence for a vasculogenic role 
for miR-126 in regulating the mobilization of endothelial progenitor cells 
via the release of chemokine SDF-1 from ischemic endothelial cells. In vitro, 
to stimulate the migration of human CD34+ stem cells. In mice however, 
systemic silencing with a single tail vein injection of antagomir-126 was not 
+/Lin- progenitor 
cells. However, in combination with the ligation of the femoral artery, we 
demonstrated an increase in circulating Sca-1+/Lin- cells following miR-126 
silencing, strongly suggesting that tissue ischemia is needed to reveal the 
regulatory role of miR-126 in vivo. 
Our data suggest that elevated numbers of circulating Sca-1+/Lin- cells in 
the antagomir-treated animals are the result of SDF-1 mediated mobilization 
of these cells following ischemia. This is supported by the fact that SDF-1-
protein expression is also up regulated in the endothelial cells of the ischemic 
of a causal role of miR-126 in SDF-1 dependent mobilization of progenitor 
cells would require an in vivo blockade in the SDF-1/CXCR4 axis. For this, 
inhibitors of the interaction of SDF-1 with CXCR4, such as AMD3100, 
could be administrated to antagomir-126 treated mice and used to alleviate 
the elevated progenitor cell mobilization following ischemia. This approach 
is however complicated by the direct effects of these inhibitors on the egress 
of progenitor cells from the bone marrow which could potentially override 
the SDF-1 effects elicited by the endothelium in the ischemic tissues in the 
periphery28. Also, impaired progenitor homing to the ischemic tissue or the 
spleen cannot be fully excluded29. 
An interaction between miR-126 and SDF-1 has previously been shown 
to increase miR-126 uptake of endothelial cell-derived apoptotic bodies 
by endothelial cells. This resulted in increased SDF-1 expression through 
30. In contrast, our 
studies implicate that the abrogation of miR-126 is associated with increased 
expression of SDF-1, suggesting that miRNAs could serve as a biological 
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rheostat, with the response magnitude of biological pathways being dependent 
on the context and source of the external stimulus.
Recently, it has been demonstrated that miRNAs are present in the 
be associated with disease states31,32. These early reports mainly displayed a 
link between circulating miRNAs and cancer, while subsequent studies have 
also revealed a clear association of circulating miRNAs with cardiovascular 
disease33-35. Since endothelial injury is considered one of the hallmarks of 
patients at risk for cardiovascular disease and, upon injury, endothelial cells 
can secrete miRNA-containing microvesicles36-38, it is of interest to address 
the value of endothelial cell-derived circulating miRNAs as biomarkers for 
cardiovascular disease. Indeed, two recent clinical studies revealed a decrease 
in circulating miR-126 levels in patients with coronary artery disease (CAD)39 
and diabetes mellitus 2 (DM2)40. It was suggested that lowered levels of miR-
126 in DM2 patients might be explained by the fact that high glucose levels 
can lead to a decrease of the miR-126 content in the endothelial particles, 
while cellular miRNA levels remained unaltered40. One may speculate that 
Figure 4. MiR-126 acts as a vasculogenic switch. In viable endothelium miR-126 inhibits 
Furthermore, the expression of SDF-1 and VCAM-1 are inhibited. When miR-126 is lost, 
SPRED-1 and PI3KR2 are up regulated thereby blocking angiogenesis, at the same time 
SDF-1 and VCAM-1 levels are up regulated and this elevation subsequently leads to an 
increased mobilization and adhesion of bone marrow derived progenitors. 
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endothelium to increase the expression levels of distinct miR-126 targets that 
are critical for the integrity of the endothelium. 
We suggest here that miR-126 functions as a regulator of endothelial 
homeostasis (Figure 4). In the healthy, viable endothelium, miR-126 is 
readily expressed and serves to down regulate SPRED-1 and PI3KR2, both 
of which are inhibitors of angiogenic and cell survival signals in response 
22,24. This condition favors 
the angiogenic response to injury, as SDF-1 expression is concomitantly 
repressed by miR-126. On the other hand, under conditions associated with 
endothelial cell dysfunction or senescence, a decrease in miR-126 levels 
would inhibit angiogenic and cell survival signals. Furthermore, this condition 
favors the expression of SDF-1 and VCAM-141 of the affected endothelial 
cells and support re-endothelialization by a vasculogenic response through 
the recruitment and subsequent adhesion of vascular progenitor cells. As 
bone marrow-derived CD34+ cells were recently demonstrated to represent 
a more functional EPC population than Sca-1+/Lin- progenitor cells, future 
studies may include these progenitor cell population as well42.
Although speculative, our model is supported by the observed decreased 
levels of circulating miR-126 in DM2 and CAD patients39,40 and elevated levels 
of SDF-1 in patients with acute coronary syndrome (ACS)43. Future studies 
in patient cohorts will provide insight as to whether the down regulation of 
circulating miR-126 can be correlated with increased levels of SDF-1. 
In conclusion, both in vitro and in vivo, miR-126 can regulate the expression of 
SDF-1 in endothelial cells, which may lead to the mobilization of Sca-1+/Lin- 
progenitor cells into the peripheral circulation following conditions of acute 
ischemia. As the endothelial miR-126 regulates both features of angiogenesis 
as well as vasculogenesis, a regulatory role for this miRNA in endothelial 
homeostasis is proposed.
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Abstract
Ischemia/reperfusion injury (IRI) is a central phenomenon in kidney 
transplantation and acute kidney injury. Integrity of the renal peritubular 
capillary network is an important limiting factor in the recovery from IRI. 
MicroRNA-126 (miR-126) facilitates vascular regeneration by acting as an 
angiomir and by modulating mobilization of hematopoietic stem/progenitor 
cells. We hypothesized that overexpression of miR-126 in the hematopoietic 
compartment could protect the kidney against IRI via preservation 
of microvascular integrity. Here we demonstrate that hematopoietic 
overexpression of miR-126 increased neovascularization of subcutaneously 
Following renal IRI, mice overexpressing miR-126 display a marked decrease 
the peritubular capillary network in the corticomedullary junction and 
increased numbers of bone marrow-derived endothelial cells. Hematopoietic 
overexpression of miR-126 increases the number of circulating Lin-/Sca-
1+/cKit+ hematopoietic stem and progenitor cells. In addition, miR-126 
overexpression attenuates CXCR4 expression on Lin-/Sca-1+/cKit+ cells in 
the bone marrow and increases renal expression of its ligand SDF-1, thus 
favoring mobilization of Lin-/Sca-1+/cKit+ cells towards the kidney. Taken 
together, overexpression of miR-126 in the hematopoietic compartment is 
associated with SDF-1/CXCR4-dependent vasculogenic progenitor cell 
mobilization and promotes vascular integrity and support recovery of the 
kidney following IRI.
 




Ischemia/reperfusion injury (IRI) is a central event in clinical conditions such 
as acute kidney injury and organ transplantation and is strongly associated 
with delayed graft function and long-term graft survival.1-3 Emerging evidence 
indicates that the renal microvascular endothelium of the outer medullary 
peritubular network is the primary site of injury in the pathogenesis of ischemia-
induced renal dysfunction.4 Following ischemia, perfusion of the peritubular 
capillary network is rapidly impaired as a consequence of endothelial cell 
(EC) swelling,5 impaired vasorelaxation6 and increased leukocyte adhesion.7 
In addition, microvascular destabilization initiated by the loss of EC-EC-8 
capillary density due to microvascular rarefaction.8, 9 The resulting loss in 
renal perfusion can further exacerbate medullary ischemia and drive the 
10 As a consequence, integrity 
of the peritubular capillary network is a key determinant for the preservation 
of renal function. Indeed, clinical biopsy studies have shown an association 
between loss of tubular structure and function on the one hand and capillary 
rarefaction on the other.11, 12
Due to their limited replicative capacity, renal ECs are thought to be 
peritubular capillary plexus after IRI.13, 14 Therefore, current therapeutic 
strategies to prevent microvascular loss have focused on the prevention 
of pericyte perturbation to reduce capillary rarefaction,15-18 However, once 
revascularization required to reverse renal dysfunction.19 In search of ways 
to augment neovascularization in the injured kidney many laboratories have 
investigated the biology and therapeutic use of circulating vascular progenitor 
cells originating from the bone marrow (BM) compartment.20 These 
progenitor cells were shown to incorporate into the injured microvasculature 
in experimental models for glomerulonephritis,21 ischemic nephropathy22, 23 
24 This phenomenon has been particularly observed 
when extensive or repetitive endothelial injury occurs, for example in kidney 
transplantation.25 Microvascular incorporation of BM-derived progenitor 
cells has been linked to preservation of the vasculature as they may serve as 
an alternative cellular source to facilitate re-endothelialization.26 In addition, 
the CXCR4+ fraction of progenitor cells is mobilized to the ischemic kidney 
by local secretion of the chemokine stromal cell-derived factor-1 (SDF-1)23,27 
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and has been shown to exert renoprotective effects in a paracrine fashion. 
PI3K/AKT signaling in progenitor cells plays a critical role in mobilization of 
progenitors from the BM via the SDF-1/CXCR4 axis28 and their subsequent 
differentiation towards vascular cells.30 MicroRNA-126 (miR-126) is a 
key regulator of PI3K/AKT signaling by direct targeting of the negative 
29-31 In addition, miR-126 
was shown to co-regulate the expansion and mobilization of hematopoietic 
stem/progenitor cells.32, 33 We hypothesized that miR-126 overexpression 
in the hematopoietic compartment of mice can enhance the vasoprotective 
potential of these progenitors and this will translate to decreased renal injury. 




Generation of mice overexpressing miR-126 in the hematopoietic 
compartment
To investigate the pro-vasculogenic effect of  miR-126, we generated mice 
overexpressing miR-126 in the hematopoietic compartment. To that end, 
mice were transplanted with lineage-negative enriched CD45.1+ BM cells 
transduced with a lentiviral vector (LV) driving the expression of  miR-126 
and dsRed under control of  a constitutive human U6 and a phosphoglycerate 
were obtained. Smears of  peripheral blood (PB) and BM of  transduced 
the transplanted BM (Figure 1A). FACS analysis for the expression ratios 
between congenic markers CD45.1 (donor) and CD45.2 (acceptor) in PB 
and BM of  the transplanted mice demonstrated high levels of  chimerism 
(Figure 1B), as CD45.1 expression in the control group (LV-C) and miR-126 
overexpression group (LV-126) was similar to CD45.1 expression in donor 
P<0.001) and 
6.0-fold (Figure 1D, P<0.05) higher expression level of  miR-126 in BM and 
PB cells, respectively, in the LV-126 group compared to the LV-C group. 
observed that mRNA levels of  7 out of  9 established miR-126 targets in 
total BM were reduced in the LV-126 group compared to LV-C controls 
(Supplementary Figure 2). 
Hematopoietic overexpression of  miR-126 increases neovascularization 
of  subcutaneously implanted angiogenic matrigel plugs in mice 
To assess the impact of  hematopoietic overexpression of  miR-126 on 
vasculogenesis, we performed in vivo, angiogenic matrigel plug assays. 
Therefore, 7 weeks after BM transplantation, matrigel plugs enriched with 
recombinant pro-angiogenic factors SDF-1 and vascular endothelial growth 
LV-C mice. After 7 days, the skin was opened to visualize the neovasculature 
blood cells. To quantify the extent of  neovascularization, microscopic images 
were taken from both sides of  the angiogenic plugs. Figure 2A shows a panel 
of  representative microphotographs, with arrowheads indicating the blood-
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implantation. Using these photographs we counted the number of  vessels 
of  vessels in the LV-126 mice as compared to the LV-C animals (Figure 
2C, n=10, P
LV-126 mice (Figure 2D, P<0.02), which correlated directly with the levels 
of  miR-126 expression in the BM of  the mice (Figure 2E, P=0.05, r2 = 0.20). 
Immunohistological analyses of  the vascularized matrigel plugs (Figure 2F-
BM-derived, dsRed+ cells that overlap with staining for murine EC antigen-32 
Figure 1. Overexpression of  miR-126 and BM transplantation in vivo. (A) Microscopic 
images of  peripheral blood (PB) and bone marrow (BM) smears show dsRed+ cells in animals 
transplanted with either LV-C or LC-126 when compared to cells of  non-transplanted animals 
(donor). (B) Representative FACS plots demonstrate successful chimerism in PB and BM by 
CD45.1 (donor) and CD45.2 (acceptor) levels. Numbers represent percentage of  cells in 
in BM (C) and PB (D) of  LV-126 mice when compared to LV-C mice.
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(MECA32) or von Willebrand Factor (vWF)(Figure 2F and Supplementary 
Figure 3A). Around the newly formed blood vessels, cells positive for platelet 
also positive for dsRed, suggesting a BM origin.
Our data indicate that overexpression of  miR-126 in the hematopoietic 
compartment stimulates neovasculogenesis of  implanted matrigel plugs that 
possibly involves both BM-derived EC as well as BM-derived perivascular 
cells.
Figure 2. Overexpression of  miR-126 in BM cells leads to increased neovascularization 
in subcutaneously implanted matrigel plugs. (A) Representative microscopic images of  
both sides of  matrigel plugs seven days after implantation in LV-C mice (left micrographs) 
and LV-126 mice (right micrographs). Arrowheads point to neovasculature. (B) A movie still 
displaying the presence of  red blood cells in the neovasculature of  the matrigel plugs. (C) 
*P<0.01, #P<0.10.
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MiR-126 overexpression in the hematopoietic compartment protects 
against renal IRI
126 in the hematopoietic compartment we hypothesized that these mice 
would be less susceptible to IRI due to an improved capacity to maintain 
renal microvascular integrity. To investigate this hypothesis, 8 weeks after 
BM transplantation, LV-126 and LV-C mice were subjected to bilateral renal 
 Renal 
IRI resulted in extensive renal dysfunction in the LV-C mice as shown by 
increased blood levels of urea (Figure 3A). In contrast, mice overexpressing 
miR-126 were protected against renal dysfunction, with a moderate elevation 
in urea levels as compared to control mice. At 72 h after reperfusion this 
deterioration of renal function in the LV-C mice was accompanied by a 
lower mRNA levels of the tubular injury markers kidney injury molecule-1 
(IL-10) (Figure 3C). In addition, analyses of post-IRI, H&E stained kidney 
less acute tubular necrosis (ATN) and tubular cast formation (rating 0-3) 
compared to the LV-C mice (Figure 3E). Direct immunohistochemical 
1 (2.6-fold) in the LV-126 group (Figure 3F, P<0.001). Tubular injury after 
+ leukocytes 
F4/80+
+ granulocyte count as a result of overexpression of miR-
126 (Figure 3I). As miR-126 has been described to positively regulate mast 
cell proliferation and cytokine production,34 we stained the sections with 
toluidine blue to determine the mast cell content of the kidneys, but could 
not observe any positive mast cell staining in the kidneys of either group (data 
not shown).
To determine whether the early protective effects observed in the LV-126 
of IRI35
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compared to those of the LV-C mice (Figure 3D). 
Figure 3. miR-126 protects against renal IRI. (A) miR-126 overexpression results in 
decreased blood urea levels after IRI. (B) miR-126 overexpression results in less weight 
or decrease is relative to LV-C group. (E) Representative images of  H&E staining on LV-C 
Representative images of  staining for tubular damage (E, KIM-1), leukocytes (F, CD45), 
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Hematopoietic overexpression of miR-126 preserves capillary density 
after IRI and is associated with increased numbers of BM-derived 
peritubular capillary EC
To determine the impact of hematopoietic miR-126 overexpression on renal 
vascular integrity after IRI, we assessed the density of the peritubular capillary 
network by staining for MECA32 before and after IR. We focused on the 
corticomedullary junction since it is known that this region is disproportionally 
damaged by IRI.4 As shown in Figure 4A and 4E we observed that the density 
of MECA32+ peritubular capillaries in the LV-C mice was markedly decreased 
three days post-IR, while microvascular density was virtually maintained in 
based on their dsRed positivity. Notably, a 2.2-fold increase was observed in 
the number of dsRed+ BM-derived cells in the kidneys of the LV-126 mice as 
compared to the LV-C group (Figure 4B and 4H). Importantly, this increase 
was IR-dependent, as the number of dsRed+ cells in the LV-126 mice in the 
non-IR group was comparable to that of the LV-C mice (Figure 4F-H). Since 
 leukocytes 
or the macrophage content between the two experimental IRI groups, we 
sought to determine the cell type that could be responsible for the increase in 
dsRed+ cells. Based on the interstitial localization of the dsRed+ cells we could 
exclude that they were tubular epithelial cells. Double staining of kidneys for 
dsRed and the endothelial marker CD31 demonstrated that a major fraction 
of the BM-derived dsRed+
these BM-derived capillary EC (CD31+/dsRed+
fold increase (P=0.04) in the LV-126 group compared to the control group 
(Figure 4D). 
detected numerous dsRed+ cells co-staining for MECA32 integrated into 
networks of MECA32+/dsRed- ECs (Figure 4I-K). In concordance with the 
results of the matrigel plug assay, also in the kidney we observed co-localization 
of dsRed +CD31+ cells were 
also found in the endothelium of the larger vessels (Supplementary Figure 
5A) and at a lower rate in the glomeruli of the LV-126 mice (Supplementary 
Figure 5B). We conclude that overexpression of miR-126 in the hematopoietic 
compartment aids to preserve the integrity of the renal microvasculature 
following IRI and associates with an increased incorporation of BM-derived 
cells into the vasculature. 
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Figure 4. MiR-126 preserves capillary density by increasing incorporation of BM- 
derived EC. 
staining in corticomedullary junctions show higher capillary density in mice that overexpress 
dsRed staining in the kidney show increased dsRed signal in LV-126 mice. (C) Representative 
higher numbers of BM- derived EC in the miR-126 group. (EF) Representative microscopic 
images and (
junctions of non-ischemic kidney shows no differences as a result of miR-126 overexpression. 
correspond to images) shows overlap of MECA32 and dsRed.
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LV-126 mice display increased hematopoietic stem- and progenitor 
cell numbers in the circulation following IRI
After having shown the provasculogenic effects of BM miR-126 overexpression 
in the matrigel plug assay and in the kidney after IRI, we assessed the impact 
of miR-126 overexpression on the hematopoietic system itself. Therefore, a 
detailed comparison was performed of the composition of cells in the BM 
and in the circulation in LV-126 and LV-C mice (Supplementary Table 1 
and 2). Little to no differences were observed in the number of white blood 
cells (WBCs), red blood cells (RBC), platelets (plt), hemoglobin (Hgb) or 
hematocrit (Hct) content between the two experimental groups in blood 
samples collected before and 4 and 8 weeks after BM transplantation. Also, no 
substantial differences were found in absolute numbers of T-cells, B-cells, NK-
cells, plasmacytoid dendritic cells (pDCs), neutrophils or eosinophils. Since 
circulating myeloid cells are known to display pro-angiogenic properties36 and 
we previously demonstrated that pro-angiogenic cells could be cultured from 
a BM-derived immature, CD31+/Ly6Chi myeloid progenitor cell fraction37, 
the monocytic cells were further subdivided into Ly6Chi, Ly6Cmed and Ly6Clo 
the experimental groups. Next, we assessed the impact of overexpression 
of miR-126 on the number of Lin-/Sca-1+/cKit+ (LSK) and Lin-/Sca-1+/
Flk+ (LSF) hematopoietic stem/progenitor cells in PB and BM, before (pre-
IRI) and 3 days after kidney IRI. While the absolute numbers of circulating 
LSK (Figure 5A) or LSF cells (Figure 5B) before kidney IRI did not differ 
and LSF cells in PB were induced 2.5- and 1.5-fold respectively (P<0.05 for 
both). Concomitant with their elevation in the circulation, BM-levels of the 
LSK and LSF cells were decreased, supporting enhanced mobilization of 
these cells from BM to the periphery after overexpression of miR-126.
Correlation analysis (Table 1) revealed a strong positive correlation between 
the expression level of miR-126 in the BM and LSK cell number in PB. 
The number of LSK cells correlated positively with capillary density (MECA 
staining) in the kidney, while strong negative correlations were observed with 
is the driver of the observed protective effects.
CXCR4/SDF-1 signaling is affected in LV-126 mice after IRI
Since the mobilization of LSK and LSF cells was markedly increased in the 
LV-126 mice we sought to determine whether overexpression of miR-126 
in the hematopoietic compartment was also associated with a shift in the 
balance between BM and peripheral SDF-1/CXCR4 signaling. As CXCR4 
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expression retains hematopoietic stem and progenitor cells in the BM and 
its inhibition can be employed to mobilize these cells from the BM,38 we 
Indeed, CXCR4 expression was selectively reduced on BM-LSK cells in the 
LV-126 group, while Lin+ cells showed an elevated expression of CXCR4 
Figure 5. Overexpression of miR-126 results in increased hematopoietic stem/
progenitor cell levels in PB and altered CXCR4/SDF-1 signaling. (A) FACS analysis 
of Lin-/Sca-1+/cKit+ (LSK) and (B) Lin-/Sca-1+/Flk+ (LSF) cells in PB and BM shows 
an increase of these circulating cells after injury after miR-126 overexpression. (C) FACS 
CXCR4 in LV-126 group, while (D) the dsRed+ LSK cells shows a decreased MFI for 
CXCR4 in LV-126 group. (E) qRT-PCR in kidneys shows increased SDF-1 mRNA levels in 
response to miR-126 overexpression in BM, while in non-ischemic kidneys this increase is
of SDF-1 staining in kidney sections show increased SDF-1 expression in miR-126 
overexpressing mice.
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(Figure 5C-D). This relative loss of CXCR4 expression on LSK cells in miR-
126 overexpressing BM (Figure 5D) may cause the selective mobilization 
of these cells to the periphery (Figure 5A). On the other hand, recruitment 
of hematopoietic stem and progenitor cells to ischemic tissue is dependent 
on SDF-1 expression at the site of injury.27, 39 As shown in Figure 5, in the 
tubuli of post-ischemic kidneys of LV-126 mice, both SDF-1 mRNA (5E) 
both 3 days as well as 3 weeks after IRI, while SDF-1 mRNA expression 
levels were not changed in non-ischemic kidneys. 
 correlation  miR-126 LSK LSF urea  MECA Kim-1 Kim-1 NGAL dsRed 
material   BM PB PB serum  kidney  kidney  kidney  kidney  kidney  
method   PCR FACS FACS  IHC PCR IHC IHC IHC 
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Table 1. Statistical analysis between different research indices. p=propability values; 
(p<0.05).




Here we describe that overexpression of miR-126 in the hematopoietic 
compartment augments neovascularization in subcutaneously implanted 
matrigel plugs and protects the kidney from IRI. Protection of the kidney and 
progenitor cells. In its turn, mobilization of LSK cells and the integration of 
dsRed+ cells in the renal microvascular network in the LV-126 mice were 
directly related to BM miR-126 expression levels. Therefore, our data support 
a direct causal role for miR-126 augmented vasculogenesis leading to the 
preservation of renal function following IRI. 
One mechanism by which miR-126 augments vasculogenesis is by selectively 
enhancing the mobilization of potentially vasculogenic stem and progenitor 
cells. Elevated SDF-1 expression by the kidney following IRI is known to be a 
main driver of the homing of BM-derived progenitor cells to the injured kidney 
by altering the balance of SDF-1 expression from the BM to the periphery.27, 
39, 40 However, it has been demonstrated that plasma elevation of SDF-1 also 
mobilizes Lin+ leukocytes.41 
the circulating hematopoietic cells in the LV-126 mice demonstrated selective 
mobilization of LSK and LSF cells in response to elevated SDF-1 expression 
by the ischemic kidney. A possible explanation for this observation could 
be that, in the BM, only the LSK cells displayed lower CXCR4 expression 
while the lineage-positive leukocytes expressed increased levels of CXCR4 
and therefore would have a higher propensity to be retained in the BM.38 
Several studies have described a regulatory role for miR-126 in SDF-1/
CXCR4 signaling. MiR-126 was shown to target SDF-1 directly33, 42 but also 
an autoregulatory feedback loop that increases the production of SDF-1.43 
renal epithelial SDF-1 expression by the LV-126 mice. Although speculative, 
miR-126 could be increased in the tubular epithelial cells by lateral transfer 
through the fusion of miR-126 rich, blood cell derived microvesicles as it was 
recently described that injection of endothelial progenitior cell (EPC)-derived 
miR-126 rich microparticles exerted a protective effect in IRI.44 Alternatively, 
the increased number of BM-derived EC that line the microvascular network 
of the kidney of the LV-126 mice could serve as a source of miR-126 via the 
production of microparticles,45 as it was recently shown that, under certain 
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conditions, such particles can cross the tubular basement membrane.46 In 
addition, activated platelets may be involved as miR-126 is among the most 
abundant miRNAs in platelets47, 48 and they could serve as transporter of miR-
126 to the site of injury49. As EPCs can take up platelets and their molecular 
content50, platelets could also add to EPC function through miR-126 transfer. 
Furthermore, platelets have been shown to constitute a rich source of local 
SDF-1 deposition themselves51. 
We propose that preservation of the capillary density in the LV-126 kidneys 
following IR is a major contributor to the protected kidney function in the 
LV-126 mice. As this maintenance of vascular integrity after IR is associated 
with an enhanced incorporation of BM-derived dsRed+ endothelial cells and 
pericytes we propose that overexpression of miR-126 in the hematopoietic 
compartment improves microvascular repair as compensation for the loss 
of capillaries. In addition, BM-derived EC and/or perivascular cells that 
had already been incorporated into the kidneys prior to IRI, could be more 
resistant to injury due to miR-126 dependent enhancement of pro-survival 
AKT signaling30, 31 and therefore add to the protection after IRI. 
Next to the effects on their mobilization, hematopoietic overexpression 
vasculogenic stem and progenitor cells via its actions on AKT signaling.29-31, 52 
For instance, it was recently shown in preeclampsia that miR-126 modulates 
the proangiogenic properties of EPC through targeting PI3KR2,53 which also 
appears to be affected in our study (Supplementary Figure 2). Augmenting AKT 
signaling in vascular progenitor cells could be particularly relevant in kidney 
disease as most patients are characterized by a state of EPC dysfunction.54, 55 
In addition, kidney graft function and the use of immunosuppressants were 
shown to directly affect EPC number and survival.56-58 
In addition to BM-derived EC, we observed dsRed+ cells expressing the 
of dsRed+ cells in the kidney were shown to be most likely pericytes. This 
suggests that also pericytes originated from BM. Support for this notion is 
emerging in literature, where the role of BM-derived pericytes is increasingly 
discussed.59, 60 
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Taken together, we demonstrate that enhancing the vasculogenic potential 
by overexpression of miR-126 in the hematopoietic compartment protects 
progression of kidney disease. Therefore, strategies aimed at improvement of 
the endogenous vasculogenic potential such as described in this study would 
not only enhance the mobilization of the vasculogenic progenitors to the 
injured kidney but may also correct EPC dysfunction in renal disease.




(CD45.1+) mice were obtained from Charles River (Maastricht, the 
Netherlands). All animal experimental protocols were approved by the animal 
welfare committee of the Leiden University Medical Center.
Lentiviral vectors 
Stable expression of miR-126 in BM-derived Lin- cells was accomplished using 
vector, the coding sequence of murine miRNA-126 is preceded by the human 
U6 gene promoter and followed by a reporter gene cassette consisting of the 
Discosoma spec. (Supplementary Figure 1A).61 The shuttle plasmid encoding 
U6 gene promoter and murine miRNA-126-coding sequence (Supplementary 
Figure 1A). LV particles were produced in 293T cells with the aid of the 
packaging plasmids psPAX2 (Addgene, Cambridge, MA, USA) and pLP/ 
described.62
collected and freed of cellular debris by centrifugation at room temperature 
for 10 min at 825×g
USA) in phosphate-buffered saline (PBS) was carefully layered under 30 ml 
of the cleared culture medium, which was then centrifuged for 2 h at 15,000 
rotations per minute for 2 h at 10ºC in an SW28 rotor (Beckman Coulter, 
Woerden, the Netherlands). Next, the supernatant was discarded and the 
serum albumin (BSA; Sigma-Aldrich, St. Louis, MO, USA) by gentle rocking 
overnight at 4ºC.
Transduction and transplantation of BM cells
BM cells were isolated from the femora and tibia of CD45.1+ mice and 
were enriched for Lin- cells using a Lineage Cell Depletion Kit (Miltenyi 
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- cells (80-90% 
purity, Supplementary Figure 1B) were grown in StemSpan-SFEM (Stemcell 
Technologies Inc, Vancouver, BC, Canada) supplemented with 50 ng/mL 
recombinant mouse stem cell factor (rmSCF), 10 ng/mL recombinant mouse 
thrombopoietin (rmTPO) and 50 ng/mL recombinant mouse fms-related 
tyrosine kinase 3 ligand (rmFLT3-L) (all from R&D Systems, Minneapolis, 
MN, USA). After 24 h the cells were transduced with either LV.hU6.
MO, USA) and maintained for another 24 h in supplemented StemSpan-
SFEM. Transduced CD45.1 donor cells (300.000/mouse) were combined 
with supportive spleen cells (500.000/mouse) and injected into the tail vein 
Matrigel plug assay
Seven weeks after transplantation, mice were injected subcutaneously into the 
supplemented with 100 ng/mL recombinant mouse SDF-1 (Invitrogen) and 
opened to monitor the vasculature of the implants with a Sidestream Dark 
Field (SDF)-camera. Subsequently, implants were extracted, imaged with a 
Leica DMI6000microscope (Leica Microsystems, Rijswijk, the Netherlands) 
images of the matrigel implants the number of visual vessels were counted on 
both sides of the implants. To obtain the total length of the vessels, pictures 
were digitalized and the total pixel area of the vessels was calculated using 
Mouse model for ischemia reperfusion injury 
Eight weeks after transplantation the renal artery and vein of mice were 
clamped bilaterally for 15 minutes using surgical clamps (S&T, Neuhausen, 
Switzerland) followed by reperfusion as described previously.63  Kidney 
function was determined by measuring urea in serum samples using standard 
auto-analyzer methods by our hospital research services. Kidneys were 
recovered either 72 hours or 3 weeks after reperfusion for immunohistological 
analyses and assessment of gene expression.
Immunohistology
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slide and subsequently blocked with 2% fetal calf serum (FCS, Bio Whittaker/
Cambrex, Verviers, Belgium), 3% bovine serum albumin (BSA, Sigma 
Aldrich) in PBS. For stainings involving horseradish peroxidase (HRP)-
conjugated secondary antibodies, endogenous peroxidase was blocked with 
H2O2
murine KIM-1 (R&D systems), F4/80 (Abcam, Cambridge, UK), CD45 
Amsterdam, the Netherlands), dsRed (LSBio, Seattle, WA, USA), MECA32 
Westgrove, PA, USA) or labeled with Alexa-488 or Alexa-568 (Molecular 
stainings were visualized using Nova RED (Vector Labs, Peterborough, 
UK) and counterstained with hematoxylin. Mast cells were stained by 
+dsRed+ double stained cells was performed 
in a blinded manner by manual counting. H&E staining was performed on 
snap-frozen kidney sections by standard methods. Histological evaluations 
for acute tubular necrosis and tubular cast formation were performed in a 
blinded manner by two independent observers.
RNA isolation and qRT-PCR analysis
Total RNA was isolated from kidney sections using Trizol reagent (Invitrogen). 
Reverse transcription was performed using a 5-minute 65ºC incubation of 
250 ng total RNA with dNTPs (Invitrogen) and oligo(dT) (Invitrogen) or 
Bleiswijk, the Netherlands). For mRNA detection, cDNA was synthesized 
using a M-MLV First-Strand Synthesis system (Invitrogen) and validation 
sequences can be found in Supplementary Table 3. Levels of expression 
were normalized on RNU6B levels obtained from the same RNA. Results 
Detection System (Bio-Rad Laboratories, Veenendaal, the Netherlands).
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Flow cytometry and blood and bone marrow analysis
Whole blood was collected by incision of the tail vein or heart puncture and 
analyzed using a semi-automatic hematology analyzer (Sysmex F-280; Sysmex 
Corporation, Etten-Leur, the Netherlands), microscope (LSM 700, Leica) 
obtained included white blood cell counts (WBC, n*106/mL), red blood cell 
counts (RBC, n*109/mL), platelets (Plt, n*106/mL), hematocrit (Hct, %/%) 
and haemoglobin (Hgb, mmol/L). For microscopic images a smear was made 
6 BM cells for 30 
minutes at 4ºC with directly conjugated antibodies against CD45.1-PE-Cy7 
(BD), CD45.2-APC-Cy7 (BD), B220-APC-Cy7 (eBioscience), CD11b-APC 
(R&D Systems) and Ly6C-FITC (Bioconnect, Huissen, The Netherlands). 
A separate sample was prepared for incubation with Sca-1-FITC (BD), 
CD117-PerCP-Cy5.5 (BD) and a cocktail against lineage-positive cells (APC-
conjugated, BD). Likewise, samples were prepared for these markers in 
combination with staining for CXCR4 (MBL international, Woburn, MA, 
USA). After labeling, cell suspensions were washed with PBS containing 1% 
BSA (Sigma-Aldrich) and 0.01% sodium azide. Erythrocytes were removed 
by addition of lysis buffer (0.155 M NH4Cl, 0.01 M KHCO3, 0.1 mM EDTA) 
the sample was incubated with an appropriate cocktail of isotype controls. 
Data were analyzed using FACS-Diva software (BD Biosciences). The 
gating strategy for peripheral blood subpopulations is described in detail in 
Supplementary Figure 6. 
Statistical Analysis
Results are expressed as mean ± standard error of the mean (SEM) unless 
stated otherwise. Statistical analysis was performed using students t-test. For 
P<0.05 
P<0.05, **; P P<0.001 
and #; P<0.10.
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Supplementary Files
Supplementary Figure 1.
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Supplementary Figure 1. Overexpression of miR-126 in Lin- bone marrow cells 
in vitro. (A) Schematic representation of the lentiviral miR-126 expression vector (pLV.
DsRed.T4) (LV-C, lower scheme). A 445 bp PCR fragment (forward primer (Sal1): 
of the constitutive U6 promoter into the Sal1 and BstB1 cloning sites of vector pLV.hU6.
to allow tracing of transduced cells. 5’ LTR, chimeric 5’ long terminal repeat containing the U3 
cPPT, HIV1 central polypurine tract and termination site; hU6, human U6 gene promoter; 
miR126, coding sequence of mouse miR-126; black box, RNA polymerase III transcriptional 
LTR, 3’ HIV1 long terminal repeat containing a deletion in the U3 region to render the LV 
self-inactivating. (B) FACS plots showing APC-labeled Lin+ BM cells, before (left panel) 
and after negative selection for Lin+- cells (middle panel) and Lin- cells. (C) Fluorescent 
transduced cells (no virus) are shown in the left panel as control. (D) FACS analysis of 
a ~20-fold increase (n=3, P<0.005) in miR-126 expression levels in cells transduced with 
the LV-126 construct as compared to the LV-C construct and non-transduced BM cells (no 
virus).




Supplementary Figure 2. Down 
regulation of established miR-126 
targets. (A) overview of the selected 
miR-126 targets including details on 
proposed functions and relevant 
tissues. (B) qRT-PCR for established 
miR-126 targets in bone marrow 
(BM) shows downregulation in LV-
126 mice as compared to LV-C mice. 
Of note,1-fold means no difference, 
expression was not detectable (nd).
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-
ferentiation of  mesenchymal stem cells toward endothelial cells via activation of  PI3K/Akt and MAPK/
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MN, Lutgens E, Wang S, Olson EN, Schober A, Weber C. Delivery of  microRNA-126 by apoptotic bodies 
induces CXCL12-dependent vascular protection. SciSignal 2: ra81, 2009.
-
tion in CD4+ T cells and contributes to systemic lupus erythematosus by targeting DNA methyltransferase 
1. Arthritis Rheum 63: 1376-1386, 2011.
6.  Shen WF, Hu YL, Uttarwar L, Passegue E, Largman C. MicroRNA-126 regulates HOXA9 by binding to 
the homeobox. MolCell Biol 28: 4609-4619, 2008.
-
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and metastasis by cancer cells. Nature 481: 190-194, 2012.
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261-271, 2008.
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Supplementary Figure 3. DsRed+ endothelial cells and pericytes in vascular 
structures in matrigel. (A) Representative confocal images of a vessel stained for EC 
(vWF, green) and dsRed (red). (B) Representative confocal images of a zoomed region and 
region indicated by white square.
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Supplementary Figure 4. Representative confocal images of  sequential kidney 
(arrows). * represents corresponding tubuli.
Supplementary Figure 5. DsRed-positive ECs in a large vessel and in a glomerulus. 
(A) representative confocal images of dsRed-positive ECs lining a large blood vessel and a 
MECA32 and dsRed. (B) Representative confocal images show a dsRed-positive glomerular 
CD31+ EC.
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BM  LV-C LV-126 LV-C LV-126 
  3d post IRI 3d post IRI 3w post IRI 3w post IRI 
CD45.1+  WBCs (n x 106/mL) 81.6 ± 6.9 73.0 ± 15.2 82.6 ± 5.0 84.9 ± 5.5 
T-cells  (n x 106/mL) 2.7 ± 0.5 2.7 ± 1.2 2.0 ± 0.8 1.6 ± 0.6 
B-cells  (n x 106/mL) 8.5 ± 2.9 7.3 ± 2.6 6.2 ± 2.4 5.3 ± 1.7 
NK-cells (n x 106/mL) 2.5 ± 1.0 2.2 ± 1.1 3.0 ± 0.5* 2.0 ± 1.2* 
pDC (n x 106/mL) 1 .4 ± 0.6* 0.8 ± 0.2* 0.7 ± 0.3 0.6 ± 0.1 
Neutrophils (n x 106/mL) 33.9 ± 5.3 30.7 ± 5.8 45.8 ± 9.6* 55.5 ± 4.6* 
Eosinophils (n x 106/mL) 4.9 ± 1.4 4.8 ± 3.2 1.9 ± 0.8 1.2 ± 0.7 














    23.6 ± 2.2* 
 
2.8 ± 1.8 
 
 20.6 ± 1.3*** 
 
0.6 ± 0.3 
 
20.4 ± 2.6* 
 
3.0 ± 2.1 
 
 15 .0 ± 3.8*** 
 
0.6 ± 0.3 
 
 
18.3 ± 2.6 
 
0.6 ± 0.4 
 
16.7 ± 2.4 
 
0.7 ± 0.4 
 
 
12.7 ± 7.1 
 
0.4 ± 0.3 
 
11.4 ± 6.3 
 
0.5 ± 0.3 
 
Supplementary Table 2. FACS analysis of  bone marrow. Values are expressed as mean 
percentages ± standard deviation of  CD45.1-positive (donor derived) cells. Values in bold 
group.
Target Gene Forward primer Reverse primer
-SMA CGTGGCTATTCCTTCGTGAC GCGTTCGTAGCTCTTCTCC



















Spred -1 GATGAGCGAGGAGACGGCGAC GTCTCTGAGTCTCTCTCCACGGA
 Supplementary Table 3. Primers for qRT-PCR analysis. 
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 A gate is 
drawn on all cells in a FCS/SSC plot (A) to exclude debris. Of the cells gated in plot A, 
the expression of CD11b (X-axis) and B220 (Y-axis) is shown in plot B, on which gates are 
placed on the CD11b-neg cells and the CD11-pos cells. The CD11-pos cells are selected in 
cells. These latter cells are selected in plot E, showing their expression of CD11b (X-axis) 
and CD115 (Y-axis): CD11b-hi/CD115-hi cells represent the monocytes and the CD11b-
dim/CD115-neg cells represent NK cells. The monocytes gated in plot E are selected in plot 
F, showing their expression of CD115 (X-axis) and Ly6C (Y-axis): Ly6C-hi cells represent 
associated monocytes. The CD11b-neg cells gated in plot B are selected in plot D and show 
their expression of the B-cell marker B220 (X-axis) and Ly6C (Y-axis): B220-neg/Ly6C-neg 
cells represent the T-cells, B220-pos/Ly6C-neg cells are B-cells, B220-neg/Ly6C-pos cells 
are activated T-cells and B220-pos/Ly6C-pos cells are plasmacytoid dendritic cells (pDCs). 
All cells were analyzed within the CD45.1 group as these cells represent the donor cells.
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Abstract
Lineage analysis has shown that during nephrogenesis, FoxD1-positive 
mesenchymal cells give rise to adult interstitial pericytes. These FoxD1-
derivative interstitial cells expand and differentiate into smooth muscle 
ureteric obstruction (UUO). Subsequently, dsRed positive cells were isolated 
kidney. In vitro we demonstrated that silencing miR-132 results in reduction 
of its established target Sirt1 and downstream Cox2. In vivo silencing of miR-
132 by antagomirs directed to miR-132 in the UUO model resulted in a 35% 
decrease in collagen deposition and decreased tubular apoptosis after 10 days 
as compared to scramblemir controls, while no difference was observed yet 
western blot and qRT-PCR analyses. No difference was observed in capillary 
density. Furthermore, we demonstrated that miR-132 silencing is associated 
with decreased Sirt1 and Cox2 expression and decreases the number of 
proliferating interstitial cells. Silencing miR-132 protects counteracts the 
associated with strongly altered Sirt1 and Cox2 levels.
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Introduction
Pericytes are stromal cells that are known to cover and support capillary 
walls. Lineage tracing of pericyte cell fate using FoxD1-Cre;Rosa26R mice 
1,2. 
MicroRNAs (miRNAs) are small ~22 nt RNAs and constitute a class of 
highly conserved non-coding RNAs hat control gene expression by inhibiting 
the translation of mRNA3. MiRNAs are able to regulate multiple targets and 
thereby provide a means for the coordinated control of gene expression. As 
a consequence, these molecules are attractive candidates for regulating cell 
4. 
Several reports already established a role for miRNAs is the development of 
and in vivo silencing of miR-21 by antagomirs reduces cardiac ERK-MAP 
5. Likewise, miR-1336
miR-2087  In 
a myocardial infarction model it was shown that members of the miR-29 
family are down regulated and miR-29 silencing with anti-miRs in vitro and in 
vivo induced the expression of collagens, whereas over expression of miR-29 
8. Also in the liver members of the 
9. In kidneys from 
rats, knockdown of miR-29b resulted in upregulation of several collagen 
genes10. 
In the kidney, several miRNAs (miR-21, -214, -324-3p, 382) are now recognized 
11-15. Also miR-
192 is involved as a tight association was demonstrated of miR-192 expression 
16,17, as well 
18.  
aimed to identify miRNAs that play an important role in the process of 
subsequently isolated these cells through FACS-sorting from healthy kidneys 
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to be dramatically increased. Since miR-132 has been described to directly 
target NAD-dependent deacetylase Sirt119 and Sirt1 is known to protect 
20 we further investigated the role of this miRNA in renal 
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Results
Accumulation of FoxD1-derivative interstitial cells in UUO in mice
by the FoxD1 promotor (FoxD1-GC). In FoxD1-GC; R26R adult mouse, 
1, 10 
To allow for cell sorting of kidney cell suspension using FACS sorting of 
ureteric obstruction (UUO) and FoxD1-derivative interstitial cells (dsRed 
contralateral kidneys (CLK). As expected, we observed a marked increase in 
of in dsRed positive pericyte-derived cells (Figure 1C).
Differential miRNA expression in FoxD1-derivative interstitial cells in 
within an in vivo renal injury setting (Figure 1D).  As shown in table 1 we found 
some miRNAs that were previously found to be differentially expressed in 
5,14 and miR-
21411. In addition, we found miR-29 family members to be down regulated, 
which are known to target collagens10. In contrast to previous studies, our 
compared to that of the pericyte control cell suspensions. Also, when validating 
the upregulation of this miRNA in total kidney (UUO versus CLK; Figure 
1E), we observed a 3-4 fold upregulation. To further assess the association of 
increased miR-132 expression in renal injury we sought to determine if miR-
132 would also be differentially regulated in a different renal injury model. 
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Figure 1. Differential miRNA expression in FoxD1-derivative interstitial cells during 
sorted cell population that are markedly increased after UUO as depicted in the histograms. 
D, heatmap representing differentially expressed miRNAs with fold change more than 1.3 
and p-values lower than 0.17. Red indicates high expression, green low expression. E, qRT-
CLK. F, qRT-PCR for miR-132 in total kidney RNA obtained 3 days after renal ischemia 
reperfusion injury as compared to kidneys from sham operated mice.
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Therefore, we induced ischemia-reperfusion injury in mice, isolated RNA 
from the kidneys 3 days after injury and measured miR-132 levels. Indeed, 
also in this renal injury model we found an over three fold  upregulation of 
miR-132 (Figure 1F). 
MiR-132 has been described to directly target Sirt119 and thereby attenuate 
expression20. Therefore we assessed whether miR-132 could also play a role 
through targeting Sirt1. 
silence miRNA expression both in vitro as well as in vivo21. Here, we employed 











8,80E-06 0,00222 125167,44 1405838,75 11,2 mmu-miR-146b
0,000 5411 0,0668 300290,57 4273538,8 14,3 mmu-miR-223
0,0007948 0,0668 111408,45 658123,93 5,9 mmu-miR-342-3p
0,0036602 0,169 462549,95 3083917,85 6,7 mmu-miR-150
0,0042723 0,169 45198,89 179091 4,0 mmu-miR-574-3p
0,0045003 0,169 382274,52 153939,05 -2,48 mmu-miR-221
0,004864 0,169 81697,22 12130,35 -6,73 mmu-miR-455
0,0054653 0,169 38732,3 828418,64 21,3 mmu-miR-132
0,0060219 0,169 2663,3 244306,59 90,9 mmu-miR-214
0,0078164 0,197 343928,67 176584,64 -1,95 mmu-miR-27b
0,0108911 0,25 166,11 2,42 -68,56 mmu-miR-741
0,0137817 0,274 582439,88 1837951,1 3,1 mmu-miR-21
0,0148108 0,274 1,78 308,9 175,4 mmu-miR-199a -5p
0,0152064 0,274 1099753,64 4653872,5 4,2 mmu-miR-146a
0,019057 5 0,307 37212,5 4528,03 -8,22 mmu-miR-708
0,0202887 0,307 729981,29 177074,88 -4,12 mmu-miR-365
0,0207106 0,307 12843,49 295,09 -43,52 mmu-miR-383
0,0290634 0,398 45829,84 1348570,58 29,4 mmu-miR-685
0,0300052 0,398 5,89 3216 ,63 555,6 mmu-miR-134
0,0391934 0,443 3,89 338,65 90,9 mmu-miR-294
Table 1. Differential miRNA expression. Top 20 differentially expressed miRNAs 
based on p-value. Mean of  intensities represents absolute expression level of  the miRNA. 
A positive fold change indicates upregulation in UUO versus healthy kidney. FDR is false 
detection ratio.
110    
expression in vitro
cells) were cultured in the presence of antagomir-132 for 48 hours both Sirt1 
and Cox2 protein expression were increased over two fold as determined by 
western blot, indicating that antagomir-132 indeed is able to positively affect 
these proteins (Figure 2A-D).
of antagomir-132 led to abrogation of this transition as illustrated by a 
Figure 2. In vitro silencing of miR-132 results in increased Sirt1 and Cox2 expression, 
 A, western blot for Sirt1 on NIH3T3 cells treated with 
blots. C, western blot for Cox on NIH3T3 cells treated with antagomir-132/scramblemir. 
scramblemir control.
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of antagomir-132, we repeated the experiment on pericyte-like mesenchymal 
again decreased when cultured with antagomir-132 (Figure 2H), thereby 
Figure 3. Silencing of miR-132 results in decreased collagen deposition. A, qRT-PCR 
for miR-132 in total kidney shows silencing of miR-132. B and C, representative microscopic 
images of Sirius Red staining of UUO kidneys from scramblemir (B) and antagomir-132 (C) 
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Silencing miR-132 supresses collagen deposition in vivo
investigated the effect of miR-132 silencing in a mouse model of renal 
scrambled control antagomirs (n=7 per group, 40 mg/kg), exposed to UUO 
expression was retained.
picrosirius red staining to quantify the collagen content in the kidneys. While 
no difference in kidney collagen content was observed 5 days after UUO, 10 
silencing amounting to a ~25% reduction in collagen deposition (Figure 3A, 
in the antagomir-132 treated mice 10 days after UUO (Figure 3D, P= 0.09). 
reduction in the number of apoptotic tubular epithelial cells, as determined 
by TUNEL staining, in the antagomir-132 treated cells (Figure 3EF). 
UUO
We observed a marked reduction in the number of cells staining positive for 
to the kidneys of scramblemir-treated mice 10 days after UUO (Figure 
the downregulation of the gene 10 days after UUO (Figure 4E, p<0.05). 
derivative interstitial cells1 we conclude that, following UUO, silencing of 
miR-132 impacts on the differentiation and/or proliferation of pericytes 
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 A, 
by representative microscopic images of staining for MECA on kidney sections. I, bar graph 
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No difference in capillary density
As the loss of pericytes may be associated with loss of the peritubular capillary 
network  we sought to determine the capillary density in both treatment 
groups. To that end, we stained whole kidney sections with mouse endothelial 
cell antigen (MECA). In contrast to our expectation, we did not observe 
a difference in capillary density between antagomir-132 and scramblemir 
treated mice 10 days after UUO (Figure 4HI).
Figure 5. Reduced Sirt1 and Cox2 expression in UUO kidneys of antagomir-132 
treated mice. 
and control kidneys treated with antagomir-132 or control scramblemir. Bar graphs depict 
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Antagomir-132 decreases levels of Sirt1 and Cox2 in vivo
miR-132 silencing were associated with increased expression of Sirt1 and 
formation in vitro, miR-132 silencing in UUO kidneys and control kidneys 
 Thymidine 
incorporation proliferations assays demonstrate decreased proliferation of NIH3T3 cells (A) 
and C3H/10T1/2 cells (B) treated with antagomir-132. Cpm is counts per minute. (C and D), 
interstitial cells (D) 10 days after UUO in kidneys of mice treated with antagomir-132 or the 
scramblemir control.
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Cox2 expression was only reduced in the obstructed kidney at day 10 (Figure 
also were decreased only at this time point. Western blot on pooled kidney 
proliferation. NIH3T3 and C3H/10T1/2 cells were cultured with or without 
Subsequently we analyzed the number of interstitial proliferating cells in 
scramblemir. Indeed, a decreased number of proliferating cells was observed 
in the interstitium of  antagomir-132 treated kidneys, further supporting a 
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Discussion 
When mouse kidneys are exposed to UUO, miR-132 expression is strongly 
of extra cellular matrix proteins, silencing of miR-132 leads to a reduction in 
scar tissue.
(mir-21, mir-214, miR-29) were included14. We strongly believe this illustrates 
other cell types when total kidney RNA preparations are used to identify 
differentially expressed miRNAs. This is clearly illustrated by the fact that we 
showed a 21 fold upregulation of miR-132 in the selected FoxD1-derivative 
cells in obstructed kidneys versus contralateral kidneys while in the RNA 
preparations from total kidneys miR-132 levels were only 3 fold enriched. 
in vitro, while SIRT1 protein expression in lysates of whole kidneys that were 
treated with antagomir-132 expression was markedly reduced. Since in this 
case our measurement involved whole kidney analysis, it is still possible that 
in the FoxD1-derivatve cells Sirt1 is negatively regulated by miR-132 and the 
observed decrease is due to the response of other cell types. Although Sirt1 is 
SIRT1 expression in the whole kidney extracts is not the result of the reduced 
in the treated contralateral kidneys. Clearly other indirect miR-132 dependent 
effects may be operational. 
22, 
so the lower Cox2 levels might be involved in the reduction of number of 
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Supplementary Figure 1).
132 silencing, this is a ‘long-term’ effect as after 5 days we did not observe 
this protective effect. The fact there is no difference in capillary density 
is also surprising, as peritubular capillary rarefaction is a typical feature of 
23
transition could result in detachment of pericytes from the microvascular 
interface leaving unstable capillaries that would result in rarefaction2. These 
cells. As we did not observe differences in capillary density, and found the 
protective effect to take place in a later phase, this suggests miR-132 is not 
involved in the initial, but in the later proliferating phase. This is supported by 
two different pericyte-like cell lines in vitro. In addition, miR-132 silencing has 
been described to be anti-proliferative in endothelial cells24 and in saphenous 
vein-derived pericyte progenitor cells (SVPs)25. However, the latter paper also 
described that 
with antimiR-132. These data suggest a dynamic role for miR-132, dependent 
on source, location and environment. 
Taken together, we have demonstrated differential expression of miRNAs in 
decrease in renal Sirt1 levels and our data suggest an important role for miR-




from ATCC (American Type Culture Collection, Manassas, VA). Both 
Invitrogen, Breda, the Netherlands) supplemented with 10% fetal calf 
serum (Bio Whittaker/Cambrex, Verviers, Belgium) and 1x L-glutamin 
unless otherwise indicated. Antagomir-132 or scramblemir was added in a 
concentration of 5 μg/mL.
Animal experiments
All animal experimental protocols were approved by the animal welfare 
committee of the veterinary authorities of the Leiden University Medical 
Center or protocols overseen by Animal Resources and Comparative 
Medicine at Harvard University. 
Bilateral Ischemia Reperfusion Injury of the Kidneys
C57BL/6 WT mice (n=5 per group, age=10 weeks, Charles River, Maastricht, 
the Netherlands) were used. Before surgery, mice were anesthetized and the 
surgical clamps (S&T, Neuhausen, Switzerland). In the sham-group identical 
surgical procedures were used, except that clips were not applied. After 
After 72 hours the mice were anesthetized and euthanized. Kidneys were 
removed and RNA was isolated as described elsewhere.
Unilateral Ureteral Obstruction (UUO)
Red mice were used. For antagomir studies, 8 week old Balb/c mice WT 
level of the lower pole of the kidney with two separate silk ties. Antagomir or 
control scramblemir was administrated i.v. at a dose of 40 mg/kg bodyweight 
24 hours before surgery.
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 For miRNA cDNA synthesis, total RNA was reverse transcribed using the 
miRNA reverse transcription kit (Applied Biosystems, Foster City, CA, 
USA) in combination with the stem-loop Megaplex Human primer pools 
A V2.1 (Applied Biosystems) according to manufacturer’s instructions. For 
each cDNA sample, 384 microRNAs including 6 controls (RNU44, RNU48, 
(Applied Biosystems) according to manufacturer’s instructions. All arrays 
were run on a 7900HT Fast Real-Time PCR System (Applied Biosystems) 
and default thermal-cycling conditions. For each array the obtained Ct-values 
were converted to relative quantities normalized to RNU48. 
RNA isolation and qRT-PCR analysis
 Total RNA from kidneys was isolated using Trizol reagent (Invitrogen, Breda, 
The Netherlands). Reverse transcription was performed using a 5 minute 
65ºC incubation of 250 ng total RNA with dNTPs (Invitrogen) and oligo(dT) 
Applied Biosystems). cDNA was synthesized using a M-MLV First-Strand 
Synthesis system (Invitrogen). Validation of mRNA levels was carried out 
 Levels of expression were determined by 
on RNU6B levels obtained from the same RNA. The following primers were 
Laboratories, Veenendaal, The Netherlands).
Western Blot
Cells or tissues collected for Western Blot were lysed in RIPA buffer (50mM 
Tris-HCl pH7.5, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 
1mM EDTA, 1% Triton X-100) containing phosphatase and protease 
inhibitors. Equal amounts of proteins (~20 ug) were prepared in sodium 
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gradient gels, and electrophoresis was carried out under reducing conditions. 
Proteins were then transferred to nitrocellulose membranes (Amersham, ‘s 
Hertogenbosch, the Netherlands) that were blocked overnight with PBS with 
0.1% Tween 20 containing 5% nonfat powdered milk and incubated with 
the primary antibody in this blocking solution for 1 h at room temperature. 
The blots were subsequently washed in PBS-Tween and then incubated with 
an appropriate HRP-conjugated secondary antibody in blocking solution. 
UK), Sirt-1 (1 ug/mL, Abcam) and Cox2 (0.1 ug/mL, Abcam). Horseradish 
mL, DakoCytomation, Enschede, The Netherlands) was used as secondary 
antibody. Bound fragments were detected with chemiluminescent reagents 
(Supersignal West Dura Extended Duration Substrate; ThermoFisher 
Design of Antagomirs
Cholesterol-conjugated RNA analogs, ‘antagomirs’, (Dharmacon RNA 
technologies, Lafayette, CO, USA) were synthesized as previously 
described26. For antagomir-132 the following sequence was used: 
5’-csgsaccauggcuguagacugsususas-Chol-3’. As a control a ‘scramblemir’ was used, 
this RNA analog is constructed from a randomized nucleotide sequence which 
does not bind to any known microRNAs: 5’-asusgacuaucgcuauucgcsasusgs-
Chol-3’. The lower case letters represent 2’-O
subscript ‘s’ represents phosphorothiate linkage; ‘Chol’ represents a 
cholesterol-group linked through a hydroxyprolinol linkage.
Immunohistochemistry
ventricle with ice-cold PBS for 2 minutes. Kidneys were sagitally sectioned 
re-hydrated in water through graded ethanol. The slides were then incubated 
for 5 minutes in 0.2% phosphomolybdic acid (Sigma, St. Louis, MO, USA) to 
reduce background. The sections were incubated in picrosirius red for three 
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Landsmeer, the Netherlands). Images of complete sections were obtained 
using a Pannoramic Midi slide scanner (3DHistech, Budapest, Hungary). 
The area of collagen deposition, stained red by picrosirius red staining, was 
antigen retrieval using citrate buffer (10mM, pH 6.0) in a microwave for 
against Ki67 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) followed 
by an appropriate secondary antibody labeled with Alexa-488 (Molecular 
deoxynucleotidyl-transferase-mediated deoxyuridine 5-triphosphate nick end 
 
Immunoresearch, Westgrove, PA, USA). As a negative control, isotype-
(Vector Labs, Peterborough, UK) and counterstained with hematoxylin. 
software, whole sections were analyzed. 
FACS sorting
 Kidneys were homogenized using a gentleMACS dissociator (Miltenyi Biotec, 
using Liberase (Roche). The obtained cell suspension was sorted using the 
Proliferation assay
Proliferation was measured by the addition of 3
well; Amersham Biosciences, The Netherlands) 16 hours before cell lysis. 
The amount of 3H-thymidine incorporation was measured using a liquid 
scintillation analyzer (Tri-Carb 2900R). Responses are expressed as mean 
counts per minute of triplicate cultures.
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Statistical Analysis
Results are expressed as mean ± standard error of the mean (SEM). Statistical 
analysis was performed using student’s T-test. P<0.05 were considered 
Supplementary Files
Supplementary Figure 1. 
due to miR-132 inhibition. Cox2 is only decreased 10 days after UUO. Note that UUO itself 
ratios are indicated.
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Abstract
The collecting duct (CD) principal cells of our kidneys are critical in the 
maintenance of blood water levels, as binding of vasopressin (AVP) to its 
role for microRNAs (miRNAs) in the regulation of water and electrolyte 
transcriptional regulator of Cox2 expression and  investigated the role of 
this miR132 in diuresis in vitro and in vivo. Silencing of miR-132 in cultured 
Silencing of miR-132 in mice caused severe weight loss as a result of acute 
diuresis characterized by increased plasma osmolality and decreased urine 
AVP mRNA expression and blood AVP levels were not increased, despite the 
apical membrane in CD cells. Taken together, Silencing of miR-132 causes 
acute diuresis. Our data indicate that this is the result of a Cox2-dependent 
demonstration of water balance regulation by a miRNA.




For our body, replenishment of water losses by an equivalent intake is 
essential to maintain our volume and osmo balance, as excessive water 
retention leads to acute or chronic hyponatremia coinciding with brain 
edema or osteoporosis, whereas overhydration and dehydration are 
fundamental to hypertension and hypotension, respectively. The collecting 
duct principal cells of our kidneys are critical in these regulatory processes. 
In states of hypovolemia or hypernatremia, the anti-diuretic hormone 
vasopressin is produced within the hypothalamic paraventricular (PVN) and 
supraoptic (SON) neurons1. AVP is then processed, stored, and secreted 
into the circulation by the posterior pituitary. Upon binding to its type-2 
receptor (V2R) in renal collecting duct principal cells, AVP induces a cAMP 
signaling cascade and activation of protein kinase A (PKA), which results in 
permeable2-4. Driven by the transcellular osmotic gradient, water will enter 
present in the basolateral membrane, resulting in concentrated urine1. Upon 
correction of blood tonicity or volume, blood vasopressin levels will drop 
5. Besides this short-term effect, vasopressin 
via activation of and promoter binding by the cyclic AMP responsive element 
binding protein (CREB)6,7
X-linked or autosomal nephrogenic diabetes insipidus (NDI), respectively, 
disorders characterized by polyuria and polydipsia due to unresponsive to 
vasopressin8
principal collecting duct cells in this process.
 
AVP dependent regulation of water homeostasis can be modulated by 
9.  Accordingly, renal 
prostaglandin E2 2) is known to counteract renal vasopressin action10, 
11. In 
addition, NSAIDs transiently enhance urine concentration12. On the other 
hand, recent studies showed that inhibition of Cox by indomethacin reduced 
13
has been reported to reduce central AVP production and release14.
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Several studies have assessed the expression of microRNAs (miRNAs) in the 
kidney15,16. MiRNAs are a class of super-regulatory molecules, which control 
the expression of sets of genes that are often functionally related at the post-
transcriptional level17. Following several impressive  examples for a pivotal 
role for miRNAs in cardiovascular development and hematopoiesis18, there is 
no doubt that miRNAs will also regulate pivotal functions in renal electrolyte 
homeostasis. Indeed, functional involvement of miRNAs in kidney regulatory 
processes was shown by several recent papers. For instance, Cre-mediated 
deletion of dicer from uretic buds and its descendents, including collecting 
duct epithelium and urothelium, by using Hox7B-CRE mice resulted in 
severe hydronephrosis19. Importantly, most mice had focal microscopic 
tubular cysts originating from the collecting duct, indicating that preventing 
pre-miRNA dicing, and thus regulation by miRNAs in these segments, 
especially affects the renal collecting duct. Also, based on in vitro analysis, 
miR-192 has been suggested to have a role in aldosteron-mediated sodium 
and potassium balance20 and miR-200b and miR-717 were associated with 
alterations in renal tonicity 21. However, experimental in vivo analysis of, the 
role of miRNAs in maintaining the body’s water and electrolyte balance has 
virtually remained unexplored. 
In the present study, we aimed to identify a role for miRNAs in prostaglandin 
dependent regulation of water homeostasis. We found that miR-132 can 
directly target Cox2 and silencing of miR-132 in mice revealed a severe weight 
transport. 





Male balb/c mice were used (n=10 per group, age=8 weeks, Charles River 
Nederland, Maastricht, the Netherlands). 24 hours before i.v. tail injection 
of 40 mg/kg bodyweight of antagomir-132 or control scramblemir, mice 
and drinking water were provided ad libitum. Following antagomir injection, 
24-hours urine was collected during the days indicated. Mice were anesthetized 
hypothalamus were removed and samples for RNA and protein (kidney only) 
analysis were frozen in liquid N2. The samples for immunocytochemistry 
Blood plasma was obtained by centrifugation (15 min at 150 g at room 
temperature, no brake). The animal experiments and protocols were approved 
by the animal welfare committee of the veterinary authorities of the Leiden 
University Medical Center.
Cell culture
The cell lines NIH3T3 (3T3) and mIMCD3 (IMCD) were obtained from 
ATCC (American Type Culture Collection, Manassas, VA). 3T3 cells 
Invitrogen, Breda, the Netherlands), and IMCD cells in DMEM/HAM-F12 
medium. Both media were supplemented with 10% fetal calf serum (Bio 
Whittaker/Cambrex, Verviers, Belgium) and 1x L-glutamin (Invitrogen) at 
cells (clone 11) were grown as previously described22
transferrin, 2mMglutamine, 50 nM dexamethasone, 1 nM triiodothyronine, 
fetal calf serum and 20 mM HEPES (pH 7.4). 
Antagomir design   
Cholesterol-conjugated RNA analogs, ‘antagomirs’, (Thermo 
  were synthesized as previously 
described23. For antagomir-132 the following sequence was used: 
5’-csgsaccauggcuguagacugsususas-Chol-3’. As a control a ‘scramblemir’ was used, 
this RNA analog is constructed from a randomized nucleotide sequence which 
does not bind to any known microRNAs: 5’-asusgacuaucgcuauucgcsasusgs-
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Chol-3’. The lower case letters represent 2’-O
subscript ‘s’ represents phosphorothiate linkage; ‘Chol’ represents a 
cholesterol-group linked through a hydroxyprolinol linkage.
Plasma and urine assays
 (Siemens, country etc) were used to qualitatively determine 
a freezing point depression osmometer. Urinary AVP levels were determined 
on 10x diluted 24-hrs urine samples using an enzymatic AVP immunoassay 
(Cayman Chemical, Ann Arbor, MI, USA), according to the protocol of 
of the manufacturer. Blood samples were supplemented with indomethacin 
directly after drawing blood, to prevent ex vivo formation of prostaglandins 
that have the potential to interfere with the assay.
Cox2 3 ’UTR miR-132 reporter assay
A synthetic, double-stranded oligonucleotide spanning a 60 bp region of the 
reporter gene in the pMIR-reportTM Expression Reporter Vector System 
(Applied Biosystems, Amsterdam, the Netherlands), thereby generating pMIR-
132-report. The same construct lacking the miRNA sequence (pMIR132-
cloning and sequence of the inserts. A renilla luciferase expression plasmid 
(pRL-SV40, Promega, Leiden, the Netherlands) served as a transfection 
antagomir treatment, IMCD cells were trypsinized, resuspended in 500 mL 
or pMIR-132-reportNC, together with 150 ng pRL-SV40 were added. The cell 
Pulser II (Bio-Rad Laboratories, Veenendaal, the Netherlands). After 10 min 
recovery time at room temperature, 1.5 × 105 cells were plated in a 24-wells 
were measured using a Dual-Luciferase Assay Reporter System (Promega) in 
Western Blot
Western blot analyses were performed on cellular lysates harvested in lysis buffer 
(50 mM Tris-HCl pH7.5, 150 mM NaCl, 1% SDS, 0,5% deoxycholate,  0,5% 
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Triton X-100) containing protease inhibitors (Complete protease inhibitor 
cocktail, Roche, Basel, Switzerland). Protein equivalents were separated 
transferred to a nitrocellulose membrane (Bio-Rad Laboratories, Veenendaal, 
Aarhus, Denmark and Dr. Knepper respectively24,25. Bound primary antibody 
was labeled with HRP-conjugated secondary antibody in blocking solution. 
Bound fragments were detected with chemiluminescent reagents (West Dura 
RNA isolation and qRT-PCR analysis
Total RNA was isolated from kidney and hypothalamus using Trizol 
reagent (Invitrogen). Validation of miR-132 expression was performed 
USA) according to manufacturer’s instructions. RNU6B was utilized for 
250 ng total RNA was reverse transcribed using oligo(dT) primers and 
M-MLV First-Strand Synthesis system (Invitrogen) according to the 
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Immunohistochemistry
they were subjected to heat-induced antigen retrieval method using citrate 
buffer (10mM, pH 6.0) in a microwave for 20 min. Next, sections were 
Cox2 (Abcam) followed by an appropriate secondary antibody labeled 
with Alexa-568 (Molecular Probes). Images were made using a confocal 
In Situ Hybridization
In situ hybridization for miR-132 was performed by Bioneer (Denmark) as 
previously described26.




miR-132 directly targets Cox2
water reabsorption in collecting duct by inducing the internalization and 
. To potentially identify miRNAs involved 
in this proces, we used online available algorithms (www.microrna.org) and 
cloned part of the 3’UTR of murine COX2 in a luciferase construct and 
introduced this construct in the mIMCD3 (IMCD) collecting duct cell line. 
Following transfection with antagomir-132 or the scramblemir control, we 
found increased luciferase expression in the presence of antagomir-132 as 
compared to control scramblemir, illustrating that miR-132 can directly bind 
and regulate Cox2 mRNA expression (Figure 1A). As miRNAs are mainly 
negative gene regulators, we next investigated whether silencing of miR-132 
in collecting duct cells would lead to a de-repression of Cox2 expression. 
To that end, we used the mpkCCD collecting duct cell line that is known 
22. Indeed, both in the 
absence and presence of dDAVP silencing of miR-132 led to a modest but 
(Figure 1BC).
Next to renal collecting duct cells, renal interstitial cells have also been 
reported to express Cox2 and may thus be under regulation of miR-132. To 
test this, we used 3T3 cells as an in vitro model for renal interstitial cells and 
cultured them in the presence of antagomir-132 or scramblemir. Indeed, also 
treated with antagomir-132 as compared to the scramblemir (Figure 1DE).
Blocking miR-132 results in increased AQP2 expression in vitro
Since miR-132 targets Cox2 and Cox2-produced prostaglandins reduce 
adding antagomir-132. Surprisingly, subsequent western blot analysis showed 
does not involve direct Cox2 mediated signaling. How miR-132 mediates the 
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MiR-132 silencing in mice results in weight loss and diuresis
As, in vivo, the Cox2 expressing target cell for miR-132 could be different 
by systemic factors, we next sought to determine the effect of silencing miR-
132 on water homeostasis in mice. To keep track of physiological parameters, 
we housed the mice in metabolic cages to collect 24-hours urine following 
either 1 day or 3 days after injection, blood was collected and kidneys 
and hypothalami were isolated. To validate in vivo miR-132 silencing we 
fold downregulation of miR-132 in total kidney tissue at both 1- and 3 days 
after administration (Figure 2A). To get insight in the regional expression of 
Figure 1. miR-132 targets Cox2 and affects AQP2 expression in vitro. A, luciferase assay 
representative western blot for Cox2 in mpkccd (B) and 3T3 (D) cells and corresponding 
dDAVP stimulation illustrates miR-132 dependent regulation.
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Figure 2. Silencing of miR-132 induces diuresis. A, antagomir-132 successfully knocked 
down miR-132 in vivo in the kidney determined by qRT-PCR. B, qRT-PCR for miR-132 
in dissected kidneys shows higher miR-132 levels in medullary regions. C, representative 
expression in medulla. D, representative microscopic images of ISH illustrate predominant 
tubular epithelial localization of miR-132 and (E) knockdown by antagomir-132. F, miR-132 
silencing results in weight loss 1 day after injection as compared to scramblemir control. 
treatments results in a trend towards less water (H) and food (I) intake 1 day after injection, 
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miR-132 in the untreated kidney we dissected cortex, medulla and papilla and 
subsequent qRT-PCR analysis demonstrated that miR-132 expression displays 
a regional increase from cortex to papilla (Figure 2B). Although expression 
was found throughout the entire kidney, in situ
abundant medullary expression of miR-132 (Figure 2C) with highest levels in 
distal tubular epithelial cells (Figure 2D). Also some vascular smooth muscle 
cells clearly stained positive (Supplementary Figure 1). ISH of kidneys of 
antagomir-132 treated mice validated miR-132 silencing as miR-132 staining 
was markedly reduced (Figure 2DE).
Physiological parameters also revealed striking effects of miR-132 silencing. 
As early as 24 hours after injection, mice injected with antagomir-132 lost 0.5 
gram more body weight than scramblemir-injected mice, which corresponds 
to 2-2.5% of their total body weight (Figure 2F). 
injection, urine and drinking volumes of mice treated with antagomir-132 
thirst sensation which, in combination with polyuria, resulted in even more 
dehydration explaining the observed weight loss.  Antagomir-132 treated 
mice showed a trend towards decreased food intake, which corresponded to 
As we observed antagomir-132 induced polyuria (Figure 3A), we sought to 
determine if urine and plasma osmolality were changed. As shown in Figure 
3B we found an increase in plasma osmolality associated with a decrease in 
of these urines, assessed qualitatively using urine strips (data not shown). As 
sodium is considered to be the main determinant of plasma osmolality, we 
sodium concentration (Figure 3C). Urinary sodium did show a trend towards 
active sodium reabsorption. 
Silencing of miR-132 abrogates apical localization of AQP2 in collecting 
duct cells 
injected with antagomir-132 compared to the scramblemir treated controls 
(Figure 4AB). In contrast, when we investigated the cellular localization of 
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between both treatment groups. In kidney sections from control mice, a clear 
apical staining is observed whereas in antagomir-132 treated mice however, 
27. As 
shown in Figure 4C-E, no differences were observed.
MiR-132 silencing suppresses sodium-hydrogen exchanger 3 (NHE3) 
gene expression
Unexpectedly, despite the increased osmolality we did not measure a 
difference in plasma sodium levels. However, urinary sodium showed a trend 
towards increased levels, suggesting antagomir-132 partly inhibits active 
sodium reabsorption. Therefore we investigated gene expression of four main 
sodium transporters along the tubular system, sodium-hydrogen exchanger 
3 (NHE3), sodium-chloride symporter (NCC), Na-K-Cl cotransporter 
Figure 3. Blocking miR-132 results in a strong change in osmolality while not in 
sodium levels. A and B, plasma osmolality (A) increased after miR-132 silencing, while 
urine osmolality decreased (B). C and D, plasma (C) and urine (D) sodium levels were not 
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(NKCC2) and the amiloride-sensitive epithelial sodium channel (ENaC). 
Interestingly, a striking decrease in NHE3 was found (Supplementary Figure 
2).
Silencing of miR-132 increases urinary PGE levels
Since we demonstrated that miR-132 could directly target Cox2, we 
hypothesized that silencing of miR-132 should result in a de-repression 
determined renal prostaglandin production (which is also used as a measure 
Figure 4. miR-132 silencing results in altered AQP2 localization. A and B, representative 
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is mainly derived from medullary synthesis28
Figure 5. Increased renal PGE2 production while no increase in AVP. 
altered but showed a trend towards reduced levels. C and D, representative microscopic 
images of renal Cox2 shows interstitial (C) and tubular epithelial (D) cell positive staining. 
expression is decreased due to blocking miR-132.
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(Figure 5B). To determine where miR-132 could affect Cox2 we performed 
a staining to assess where Cox2 is expressed. Although some controversy 
exists about the location of constitutive Cox2 expression, we found it to be 
expressed in interstitial cells, cortical tubular structures (based on morphology 
 (Figure 5E). This pattern 
highly corresponds to miR-132 localization, consistent with a functional link 
between the miR and Cox2.
MiR-132 blocking attenuates hypertonicity-induced increase in blood 
AVP levels 
In normal physiology increased plasma osmolality stimulates drinking and 
secretion of AVP, resulting in increased renal water reabsorption, more 
concentrated urine, and less concentrated blood plasma. We assessed 
29, and 
surpisingly found no increase in AVP levels (Figure 5F). In fact, we see a 
trend towards decreased levels of vasopressin. Alternatively, or additionally, 
the observed effect of increased diuresis, may be due to reduced central 
14. To assess 
this hypothesis we excised the hypothalamus of the animals and determined 
AVP gene expression by qPCR. We found decreased levels of AVP gene 
expression in the hypothalamus in mice that received antagomir-132 (Figure 
AVP production providing an additional explanation for the (trend towards) 
lower urinary AVP levels.




increased plasma osmolality and decreased urine osmolality. The effects we 
observed seem to be acute, as they are present within 24 hours after injection of 
antagomir-132, while 48 hours after injection, no further weight loss or polyuria 
is found. This suggests the body responds to this interference in homeostatic 
conditions by a feedback mechanism, which seems appropriate as regulation 
of water and electrolyte balance is tightly controlled. Antagomir-132 treated 
mice showed a trend towards decreased food intake that corresponded with 
reduced feces production which is therefore no contributor to weight loss. 
However, these observations suggest the mice display signs of malaise.
(NIH3T3) that blocking miR-132 results in increased Cox2 levels. In vivo, this 
that miR-132 can have ambiguous effects, depending on the site of action. 
We found miR-132 expression predominantly in tubular structures, with 
highest levels in the renal medulla and more distant regions of the tubule. 
In addition, we observed most Cox2 expression in distant regions of the 
reported on this subject30,31. As we demonstrated that Cox2 is a direct target 
of miR-132, this suggests its regulation could be mainly taking place here. 
However, also (cortical) interstitial cells are expressing Cox2, and as we have 
increase in Cox2 expression. To elucidate the exact site of action of miR-132 
and its target(s) involved in diuresis further investigations are necessary.
translocation and subsequent increased diuresis as it is known to counteract 
10,11. In addition, AVP levels in the urine, 
29 were slightly decreased, possibly 
due to decreased AVP production in the hypothalamus as we show that 
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hypothalamic AVP gene expression is decreased as a results of antagonizing 
miR-132. These decreased levels could again be explained by an alteration 
14 although the exact mechanism needs further investigation. 
In addition, to clarify the role of central AVP production on the observed 
phenomena in this study, one needs to investigate the effect of antagomir-132 
while also providing synthetic dDAVP to the mice, which could rescue the 
phenotype if it was completely due to central AVP interference.
It has been well established that AVP also has long term effects in principal 
and promoter binding by the cyclic AMP responsive element binding protein 
(CREB)6,7. CREB itself is known to regulate transcription of miR-13232, 
providing a potential feedback loop in signaling. Furthermore, miR-132 can 
target p30033, which is a transcriptional co-activator that can act in concert 
with CREB. In addition, promoter activity of Cox2 is dependent on CREB/
p300 transcription factors34,35. These factors are adding additional layers of 
possible autoregulation within water maintenance. Besides, this might explain 
the in vitro
it has been shown that inhibition of Cox2 by indomethacin reduced renal 
13, which might also explain our in vitro observations. 
We observed an increase in plasma osmolality suggesting the mice are 
hypovolemic. This would normally be accompanied by decreased blood 
pressure and subsequent activation of the RAAS pathway. Angiotensin 
II, that will be increased due to RAAS activation, is known to exert a 
dipsogenic effect36. The dipsogenic action of angiotensin II is thought to be 
mediated by the subfornical organ (SFO), because the SFO contains a high 
concentration of the angiotensin AT1 receptor37 and ablation of the SFO 
completely abolished the dipsogenic response to angiotensin II38. However, 
we surprisingly found the polyuric mice to drink less. It could be expected 
therefore that angiotensin II signaling is disturbed. Indeed, a crosstalk 
between miR-132 and angiotensin II has been described39. Furthermore it 
was shown that miR-132 can directly target Angiotensin II type 1 Receptor 
(AT1R)40. These data suggest that also angiotensin II signaling is disturbed 
in these mice by silencing miR-132. Interestingly, NHE3 is also known to be 
regulated by angiotensin II41, so disturbed angiotensin II signaling could also 
reduce NHE3 expression, which is what we observed.
Some neurons in the above mentioned SFO are osmoreceptors, being 
sensitive to the osmotic pressure of the blood. These neurons project to 
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the supraoptic nucleus and paraventricular nucleus to regulate the activity of 
vasopressin-secreting neurons. AVP levels are known to be subject to circadian 
regulations. Also CREB mediated miR-132 expression is circadian-regulated, 
in the suprachiasmatic nucleus (SCN), where it is important for proper clock-
resetting responses to light42. Furthermore, AVP plays an important role in 
nocturnal enuresis. It is therefore that DDAVP is used as a drug to treat 
nocturnal enuresis, although this phenomenon is not mediated by the V2R 
43,44. It would be plausible however for miR-132 
to play a role in this regulation as it is involved in diuresis. Interestingly, a 
comphrehensive miRNA sequencing study indicated miR-132 to be highly 
enriched in the pituitary15, suggesting antagomir-132 could strongly affect the 
above mentioned processes at this site.
Taken together, it is evident that miR-132 plays a central role in physiology, 
miR-132 expression is crucial to associated disorders like hypertension, edema, 
Diabetes Insipidus and syndrome of inappropriate antidiuretic hormone 
hypersecretion (SIADH) .This makes miR-132 a very attractive candidate for 
future therapeutics and further investigation in physiological processes.
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SH) shows miR-132 is present in 
vascular smooth muscle cells.
qRT-PCR of 4 main sodium transporters along the tubular system 
reveals a strong decrease in NHE3 expression due to miR-132 silencing.
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General Discussion
Chronic kidney diseases occur when disorders such as diabetes, chronic 
deteriorating the structure of the organ. Patients with failing kidneys require 
dialysis or kidney transplantation, procedures that are either not successful 
in the long term (dialysis), or not always available (transplantation). As 
microRNAs (miRNAs) have been shown to be important in virtually all 
biological processes,it is no longer the question if miRNAs are involved in 
renal injury and repair but, instead, the focus is now on what critical pathways 
they modulate. Moreover, the fact that miRNAs can coordinate multiple 
genes, that are often functionally related, makes them attractive targets for 
intervention. In this thesis, we have provided compelling evidence for a 
regulatory role of miRNA-155, -126 and -132 in the pathophysiology of the 
kidney. 
In Chapter 2 we describe that miR-155 plays a rate-limiting role in endothelial 
to mesenchymal transition (EndoMT). EndoMT was originally recognized 
as a process in the developing embryo. Endothelial cells (ECs), lining the 
endocardium can dedifferentiate to cellularize the endocardial cushions in 
the development of functional heart valves1. This process is reminiscent to 
the formation of the tubular system in the kidney through mesenchymal to 
epithelial transitions during nephrogenesis2,3 as described in the introduction 
of this thesis. During EndoMT, ECs loose their expression of endothelial cell 
markers, delaminate from the surrounding monolayer, and migrate into the 
cardiac jelly4 5,6. Next 
to the physiological role of EndoMT in embryogenesis, ECs that undergo 
7-9. The analogue of EndoMT for epithelial 
cells, epithelial to mesenchymal transition (EMT), has even more often been 
10. However, the exact 
no double-staining of labeled tubular epithelial cells with markers of activated 
EMT11. The evidence for endothelial-to-mesenchymal transformation is 
built on genetic labeling of endothelial cells using ambigious markers like 
Tie-27
markers has been demonstrated. However Tie-2 is also expressed on myeloid 
cells and notably on pericytes. It is therefore very intriguing that studies 
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using sophisticated models of cell fate tracing demonstrated that pericytes 
 and not epithelial cells are the primary source 
11,12. This could mean that the processes 
of EMT and EndoMT do not contribute quantitatively to the development 
loss of capillaries. Along the same lines, loss of pericyte–endothelial cross-talk 
in response to renal injury causes microvascular rarefaction and interstitial 
in this process13. The detachment of pericytes from endothelium under 
unstable microvasculature and hence rarefaction, ultimately leading to 
nephron ischemia and loss14. 
As pericytes were demonstrated to constitute the primary source of 
Chapter 5, we used 
the same FoxD1-based murine lineage tracing model that was used to 
11, and 
sorting to isolate (differentiated) pericytes we showed a 21-fold upregulation 
of miR-132 in these FoxD1-derivative interstitial cells in obstructed kidneys 
versus contralateral kidneys. In total kidney extracts, we only found a 3-fold 
11. 
In addition, in vitro
decreased proliferation as determined by a thymidine incorporation assay, 
Antagomir-based inhibition of miRNA function was used throughout this 
thesis. Chapters 2, 3, 5 and 6 describe studies that involve miRNA silencing 
conjugated antisense oligonucleotides, which bind to its complementary 
miRNA, thereby blocking its function15. Antagomir administration almost 
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completely abrogates miRNA expression as demonstrated for example in 
Chapters 5, where, as long as ten days after injection this inhibition was 
observed. The data described in this thesis illustrates the potential therapeutic 
use of antagomir-based approaches for silencing of miRNAs. Indeed, a 
similar chemistry for antagonizing miRNA function is now investigated 
in humans in a phase II clinical trial for treating Hepatitis C16. Results of 
this study so far demonstrated that the drug was safe and well tolerated and 
resulted in decreased viral titers17.  However, only few miRNAs are as tissue 
18, as most miRNAs are present in multiple 
cell types and tissues19 and mostly have several targets and can affect very 
different pathways20,21. This makes the use of miRNA inhibitors challenging, 
as it could theoretically have multiple off-target effects. On the other hand, 
miRNAs could coordinately target multiple related genes within a certain 
pathway22, thereby making them potentially even more attractive candidates 
to therapeutically target.
That miRNAs can have pleiotropic effects is demonstrated in this thesis. First, 
in Chapters 3 and 4, we describe an increase in circulating hematopoietic 
progenitor cells that results from both systemic silencing of miR-126 (Chapter 
3) as well as from overexpression in the hematopoietic compartment (Chapter 
4). This indicates that a single miRNA can work in opposite ways depending 
on cell type and the micro-environmental context and suggests that miR-126 
could serve as a biological switch, with the response magnitude of biological 
pathways being dependent on cell type, the context and source of the external 
stimulus, and underlines the importance of miR-126 in vascular homeostasis.
A striking example of the pleiotropic actions of miRNAs is presented in 
Chapter 5 and 7. MiR-132 has been described to be present in pericytes 
this miRNA using antagomir-132 we could suppress the formation of 
Chapter 
6, using the same antagomir-132, we observed a completely different role 
for this miRNA. Here, we describe miR-132 to play an essential role in 
Aquaporin-2 mediated water reabsorption in the collecting duct through a 
prostaglandin-E2 and vasopressin dependent mechanism. This illustrates 
affect water reabsorption and thereby have harmful side-effects. In fact, in 
Chapter 5 we observed weight loss 24 hour 
after injection of the antagomir-132, while scramblemir-treated mice did 
not lose weight. This is probably due to the polyuretic effects of miR-132 
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described in Chapter 6. Although hypothetical at this point, in both chapters, 
described above, in Chapter 6 miR-132 silencing increased Cox2 levels and 
elevated renal prostaglandin-E2 levels and potentially explain the observed 
polyuretic effects. In Chapter 5, augmented prostaglandin-E2 levels due to 
these cells against apoptosis and oxidative stress23.
In Chapters 3 and 4 we focus on the role of miR-126 in vascular homeostasis. 
We previously collected data supporting a role for miR-126 in the angiogenic 
response induced by ischemia using a murine unilateral hind limb ischemia 
model24. Using this model we were able to assess the hypoxia induced 
angiogenic response in the gastrocnemius calf muscle25 and found that the 
mice treated with antagomir-126 showed a strongly reduced capillary density 
in this muscle as compared to the scramblemir-treated control mice. However, 
in vitro experiments to assess the effects of antagomir-126 silencing in human 
umbilical vein endothelial cells (HUVEC) revealed functional impairments. 
The effects of miR-126 on angiogenesis likely involve mechanisms operational 
in and on endothelial cells in the in vivo context, possibly through its interaction 
with pericytes, as results described in Chapter 4 suggest that miR-126 also 
Other groups also showed that targeted deletion of miR-126 in mice and 
related EVH1 domain-containing protein (Spred-1) and phosphoinositol-3 
kinase regulatory subunit 2 (PIK3R2) expression26,27, which are actively 
involved in the negative regulation of vascular endothelial growth factor 
28 and are both predicted targets of 
miR-12629. Consequently, low levels of miR-126 would be associated with 
elevated levels of Spred-1 or PIK3R2 and repressed angiogenic signaling, 
which makes them likely targets to be associated with the decreased ischemia-
induced angiogenesis as demonstrated in our studies. This mechanism could 
Chapter 4. Here we demonstrate that the 
angiogenic potential of miR-126 may reach beyond its presence in endothelial 
30,31. 
hematopoietic cells32-34. We over-expressed miR-126, together with a dsRed 
gene, in bone marrow cells and subsequently performed bone marrow 
transplantation. Following the restoration of the hematopoietic system, we 
induced renal ischemia reperfusion injury, and in separate mice we inserted 
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of mice. We demonstrate a protective role for miR-126 in renal ischemia 
reperfusion injury and improvement in capillary density in the kidney. In 
combination with higher numbers of bone marrow derived endothelial cells, 
as determined by dsRed and CD31 co-staining, this suggests protection 
of renal function through increased vasculogenesis or preserved vascular 
integrity by endothelial progenitor cells (EPC). Interestingly, it is known 
that circulating EPC are markedly reduced in renal failure35 and kidney graft 
function was shown to determine EPC number in renal transplant recipients36. 
Of particular interest is that immunosuppressants, already at sub-clinical 
concentrations, appear to induce rapid cell death of EPC in early stages of 
their differentiation37,38. Another important player in our study could be the 
vesicles derived from EPCs that have been shown to protect against renal 
IRI through transfer of miR-12639. Therefore, overexpression of miR-126 in 
the hematopoietic compartment could potentially contribute to protection 
against renal IRI by transfer of miR-126 via microvesicles. Together these 
observations emphasize that augmenting microvascular endothelial repair 
through miR-126 modulation may well have therapeutic implications in renal 
disease. 
To validate the role of hematopoietic miR-126 in vascular integrity, we 
performed a matrigel assay to determine whether miR-126 could contribute to 
neovascularization. We found an almost two fold increase in vascularization 
previously24. Furthermore, MECA32+dsRed+ cells were incorporated in the 
from the IRI experiment that hematopoietic miR-126 functions, at least 
partly, by stimulating vascularization. 
The observed increase in vascularization of the matrigel plug however, could 
also be due to increased recruitment of leukocyte subsets. For instance, 
extravasation of monocytes into a foreign body can results in differentiation 
into macrophages that then can support angiogenesis40,41. Subsequently, 
macrophages can contribute to angiogenesis by producing angiogenic factors 
42,43 or facilitating anastomosis of the forming vessels44. 
 In addition to bone marrow-derived EC, in the matrigel plug we observed 
also pericytes could originate from bone marrow. Support for this notion 
is emerging in literature, where the role of bone marrow derived pericytes is 
increasingly discussed45,46.
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In our study described in Chapter 4
the circulating hematopoietic cells in the mice that overexpressed miR-126 
in the hematopoietic compartment, demonstrated selective mobilization of 
Lin-/Sca-1+/cKit+ (LSK) and Lin-/Sca-1+/Flk+ (LSF) cells in response 
to elevated SDF-1 expression by the ischemic kidney. SDF-1 expression 
is induced after renal IRI47 and can augment the homing of bone marrow-
mobilized progenitor cells to sites of injury48-50. A possible explanation for this 
selective mobilization could be that, in the BM, only the LSK cells displayed 
lower CXCR4 expression while the lineage-positive leukocytes expressed 
increased levels of CXCR4 and therefore would have a higher propensity to 
be retained in the BM51. Several studies have described a regulatory role for 
miR-126 in SDF-1/CXCR4signaling. MiR-126 was shown to target SDF-1 
directly52,53
54
is thought to stimulate an autoregulatory feedback loop that increases the 
mechanism for the elevated renal epithelial SDF-1 expression observed in 
mice that overexpressed miR-126. 
In conclusion, the data described in this thesis illustrates the importance 
of miRNAs in (renal) biology. It also demonstrates the dynamic interplay 
describe roles for miR-155, miR-126 and miR-132 in vascular stability 
and differentiation of cells of the vascular system, i.e. endothelial cells and 
pericytes. MiR-126 is involved in neovascularization and maintaining vascular 
integrity, while miR-155 plays a role in differentiation of endothelial cells 
towards a mesenchymal-like cell, thereby potentially leaving the capillaries 
unstable. The same is true for miR-132, but then at the level of pericytes. 
The differentiation of these cells can result in detachment from the capillary 
thereby destabilizing it. In addition, it is reported that miR-132 in pericyte 
progenitor cells plays an important role in angiogenesis in the context of 
55. Also, tumor endothelial cells were described to contain high 
levels of miR-132 which is involved in pathological (tumor) angiogenesis56. 
This emphasizes again the spectrum of activities of a single miRNA. These 
data show that all three miRNAs are involved in renal (patho)physiology and 
maintaining vascular integrity and further emphasizes the importance of the 
cellular context of miRNA function.
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Future perspectives/Considerations
As has been shown in this thesis, miRNAs can have pleiotropic effects. 
To fully understand a single miRNA’s diverse functions, one needs to 
comprehensively study a miRNA of interest in several models, different 
(micro)environments and a variety of cell and organ types. For example, 
make it essential to employ models of lineage tracing to reveal the true role of 
the individual players as its roles may be contradictory in different cells types. 
On the other hand, to fully understand a biological process, one also needs 
to study the interplay of different miRNAs involved in the same process. 
Although the studies described in this thesis provide an important step 
towards better understanding, extensive follow up research is needed to fully 
comprehend renal miRNA biology. 
Furthermore, we can learn from other organs. For example, in animal models 
excessive production of extracellular matrix proteins57. Also, upregulation 
58
59,60.
In addition, the mechanisms underlying the regulation of miRNA expression 
itself need more investigation. If we can identify how miRNA expression is 
controlled, this provides us with the opportunity to take over control and 
modulate this expression.
In conclusion, identifying the role of miRNA involvement in all aspects and 
layers of modulation within renal functioning is a vast task and challenge, 
but one that will lead to the generation of novel therapeutic approaches to 
maintain and improve renal function after injury.
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Summary
Kidney disease is a common disorder that affects up to 10% of the population 
and this number is rapidly rising. Chronic kidney diseases occur when 
eventually lead to kidney failure. The patient then requires dialysis or kidney 
transplantation, procedures that are either not successful in the long term 
(dialysis), or not always available (transplantation). As MicroRNAs (miRNAs) 
seem to be important in virtually all biological processes it is no longer a 
question if miRNAs are involved in renal injury and repair but what critical 
pathways they modulate. Therefore, miRNAs could serve as attractive 
targets for intervention. In this thesis, studies are described in which roles 
of miRNA-155, -126 and -132 in the context of kidney functioning are 
investigated.
Chapter 1 provides a general background on the prevalence of kidney 
disease and describes the kidney and its function. In addition, evolution and 
nephrogenesis of the kidney is discussed, providing background for studies 
described in this thesis. Furthermore, the biogenesis, function and mode of 
action of miRNAs is described, followed by a short overview of the relevance 
of miRNAs for kidney functioning.
In Chapter 2 we investigated the role of miRNAs, miR-155 in particular, in 
endothelial to mesenchymal transition (EndoMT), which has been proposed 
to be involved in the loss of microvascular capillaries in the pathophysiology 
mesenchymal transition associated with the loss of cell-cell contacts and the 
in vitro 
hypoxia, which further augments EndoMT. Silencing of miR-155 directly 
increased RhoA expression and activity in endothelial cells and affected 
phosphorylation of downstream LIMK. In contrast, overexpression of miR-
155 counteracted RhoA function. Using a selective Rho kinase inhibitor, we 
could partly suppress EndoMT, strengthening the notion that RhoA plays 
a central role in EndoMT. Forced overexpression of miR-155 completely 
suppressed EndoMT, as evidenced by the maintenance of EC characteristics 
and blocking the acquisition of a mesenchymal phenotype, as compared to 
control cells. Our data demonstrate that miRNA-155 functions as a negative 




We previously showed that miR-126 plays a role in angiogenesis. Based on 
the seed sequence, miR-126 can also be predicted to regulate vasculogenesis 
by modulating the endothelial expression of stromal cell-derived factor-1 
(SDF-1). In Chapter 3 this was investigated. Using miR-reporter constructs, 
cells in vitro. Next, we investigated the potential relevance of this observation 
with respect to the mobilization of progenitor cells. For this, we studied 
the migration of human CD34+ progenitor cells towards chemotactic 
factors present in endothelial cell-conditioned medium. Antagomir-induced 
silencing of miR-126 elevated SDF-1 expression by human umbilical vein 
endothelial cells and enhanced migration of the CD34+ cells. In a murine 
model of hind limb ischemia, a striking increase in the number of circulating 
Sca-1+/Lin- progenitor cells in antagomir-126-treated mice was observed as 
compared to scramblemir-treated controls. Immunohistochemical staining 
of capillaries in the post-ischemic gastrocnemius muscle of miR-126-silenced 
mice revealed elevated SDF-1 expressing CD31-positive capillaries, whereas 
a mobilizing effect of miR-126 inhibition was not detected in healthy control 
animals. In conclusion, miR-126 can regulate the expression of SDF-1 in 
endothelial cells. In the context of an ischemic event, systemic silencing of 
miR-126 leads to the mobilization of Sca-1+/Lin- progenitor cells into the 
peripheral circulation, potentially in response to elevated SDF-1 expression 
by endothelial cells present in the ischemic tissue. 
Ischemia/reperfusion injury (IRI) is a central phenomenon in kidney 
transplantation. Managing the effects of renal IRI is crucial to short-and long-
term graft survival following kidney transplantation. The peritubular capillary 
network may well be the rate limiting factor in the recovery of IRI. Following 
integrity, in Chapter 4 we investigated if overexpression of microRNA-126 
in bone marrow cells can aid in the recovery after IRI. Using a lentiviral 
construct we overexpressed miR-126 in bone marrow cells. Subsequently 
these cells were injected into lethally irradiated mice. Eight weeks after 
reconstitution of the bone marrow the mice underwent renal bilateral IRI. 
We found functional protection against IRI as a result of overexpression 
of miR-126 as demonstrated by decreased urea levels. In addition, damage 
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cells. We demonstrated that an elevated amount of endothelial cells was 
bone marrow derived that matched the observation of increased circulating 
hematopoietic stem and progenitor cells. We show that miR-126 attenuated 
CXCR4 expression on these cells, suggesting these cells would have a lower 
hematopoietic miR-126 in a matrigel assay, where we show that overexpression 
of miR-126 results in increased neovascularization.  
compartment protects against renal ischemia/reperfusion injury through 
stimulation of hematopoietic progenitor cell mobilization that leads to an 
improvement of the renal microvasculature.
In Chapter 5
during nephrogenesis, FoxD1-positive mesenchymal cells give rise to adult 
interstitial pericytes. These FoxD1-derivative interstitial cells expand and 
(miRNAs) involved in this differentiation could serve as a target to decrease 
FoxD1-derivative interstitial cells (dsRed positive) that were isolated using 
In vitro we demonstrated that silencing miR-132 results in reduction of 
Sirt1 and downstream Cox2. 
In vivo
a ~35% decrease in renal collagen deposition after 10 days as compared to 
scramblemir controls, while no difference was observed yet after 5 days. In 
addition, immunohistochemical analyses demonstrate that the number of 
both western blot and qRT-PCR analyses. However, no difference is observed 
in capillary density. Surprisingly, silencing miR-132 is associated with reduced 
levels of Sirt-1, indicating this is not the responsible mechanism. 
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However, we demonstrated that miR-132 silencing has anti-proliferative 
effects, suggesting miR-132 plays an important role in the proliferation of 
In Chapter 6 we describe a role for miR-132 in diuresis. The collecting 
duct principal cells of our kidneys are critical in this maintenance of blood 
water levels, as binding of vasopressin (anti-diuretic hormone) to its V2-
renal vasopressin action in principal cells by inducing the internalization and 
lysosomal degradation of Aquaporin-2. Using miR-reporter constructs we 
in vitro 
Cox2 expression. Silencing of miR-132 in vivo in mice resulted in increased 
the apical membrane in collecting duct cells was disturbed. This ultimately led 
to acute diuresis and severe weight loss. These data demonstrate an essential 
role for miR-132 in water homeostasis. 
Finally, in Chapter 7, all studies described in this thesis are discussed and put 
in perspective with respect to present knowledge.
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Samenvatting
Nierziekten zijn een veel voorkomende aandoening welke tot 10% van de 
bevolking treft en dit aantal is snel groeiend. Chronisch nierfalen treedt 
op wanneer aandoening als diabetes, hoge bloeddruk, ontstekingen of 
toxische substanties op den duur tot nierschade leiden. De patient heeft dan 
niervervangende therapie nodig in de vorm van dialyse of niertransplantatie, 
procedures die niet succesvol zijn op lange termijn (dialyse) of niet altijd 
beschikbaar (transplantatie). Omdat microRNAs (miRNAs), die betrokken 
zijn in posttranscriptionele genregulatie, belangrijk lijken te zijn in praktisch 
alle biologische processen is het niet langer de vraag of miRNAs betrokken 
zijn bij nierschade en herstel, maar actueel is welke essentiele processen 
ze moduleren. Om deze reden zouden miRNAs interessante targets voor 
therapeutische interventie kunnen zijn. In dit proefschrift zijn studies 
beschreven die een rol voor miR-155, -126 and -132 beschrijven in de context 
van nierfunctie.
Hoofdstuk 1 geeft algemene achtergrondinformatie met betrekking tot de 
prevalentie van nierziekten en het functioneren van de nier in het algemeen. 
Ook wordt de evolutie en nefrogenese van de nier beschreven, welke als 
achtergrond dienen voor studies die beschreven zijn in dit proefschrift. 
Daarnaast wordt de biogenese van miRNAs samengevat gevolgd door een 
beschrijving van de werking van miRNAs en een korte overview van de 
relevantie van miRNAs in nierfunctie. 
In Hoofdstuk 2 hebben we de rol van miRNAs, met name miR-155, 
onderzocht in endotheel-mesenchymale transitie (EndoMT), waarvan wordt 
gedacht dat het betrokken kan zijn bij het verlies van microvasculaire capillairen 
(EC) ondergaan een mesenchymale transitie geassocieerd met het verlies 
van cel-cel contacten en het verkrijgen van een ‘synthetisch’, contractiel 
in vitro model voor EndoMT hebben 
wat zelf bijdraagt aan EndoMT. Het blokken van miR-155 verhoogde RhoA 
expressie en activiteit in EC en had invloed op fosforylering van downstream 
LIMK. MiR-155 overexpressie leidde tot vermindering van RhoA functie. 
gedeeltelijk onderdrukken, wat benadrukt dat RhoA een centrale rol speelt 
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in EndoMT. Overexpressie van miR-155 leidde kon het volledige EndoMT 
proces blokkeren in vergelijking tot controle cellen, zoals blijkt uit het behoud 
van EC karakteristieken en de afwezigheid van een mesenchymaal fenotype. 
Deze data demonstreren dat miR-155 als een negatieve regulator functioneert 
angiogenese (zoals we eerder aangetoond hebben) ook in arteriogenese een 
rol speelt  door middel van regulatie van de expressie van stromal cell-derived 
factor-1 (SDF-1). In Hoofdstuk 3 werd dit onderzocht. Door middel van 
miR-reporter constructen hebben we gevalideerd dat miR-126 in EC in 
vitro inderdaad SDF-1 expressie inhibeert. Vervolgens onderzochten we 
de potentiele relevantie hiervan voor de mobilizatie van progenitor cellen. 
Daarvoor bekeken we de migratie van humane CD34+ progenitor cellen 
naar chemotactische factoren  in endotheel cel-geconditioneerd medium. 
Antagomir-geinduceerd inhiberen van miR-126 verhoogde SDF-1 expressie in 
‘human umbilical vein endothelial cells’ en stimuleerde migratie van de CD34+ 
cellen. In het eerder genoemde muismodel voor ischemie in de achterpoot 
konden we een sterke toename in circulerende Sca-1+/Lin- progenitor 
cellen waarnemen  in antagomir-126 behandelde muizen in vergelijking tot 
scramblemir behandelde controle muizen. Immunohistochemische kleuring 
van de capillairen in de post-ischemische kuitspier toonden een verhoging 
aan van SDF-1 expresserende CD31-positieve capillairen als gevolg van 
miR-126 inhibitie, terwijl in gezonde controle muizen dit mobilizatie effect 
door middel van miR-126 inhibitie niet kon worden aangetoond. Kortom, 
miR-126 kan SDF-1 expressie reguleren in EC. In de context van een 
ischemisch event leidt systemische miR-126 inhibitie tot mobilizatie van Sca-
1+/Lin- progenitor cellen naar de perifere circulatie, potentieel ten gevolge 
van verhoogde SDF-1 expressie door endotheel cellen die aanwezig zijn in 
ischemisch weefsel.
Ischemie/reperfusie schade (IRI) is een centraal fenomeen in niertransplantatie. 
Het managen van de effecten van nier IRI is cruciaal voor korte- en lange 
termijn overleving van de getransplanteerde nier na transplantatie. Het 
peritubulaire capillaire netwerk zou zeer goed de centrale factor kunnen zijn 
in het herstel na IRI. Naar aanleiding van onze eerdere bevindingen dat miR-
126 een centrale rol speelt in vasculaire integriteit, hebben we in Hoofdstuk 
4 onderzocht of overexpressie van miR-126 in beenmerg cellen kan helpen bij 
het herstel na IRI. Met behulp van een lentiviraal construct hebben we miR-
126 tot overexpressie gebracht in beenmerg cellen. Vervolgens werden deze 
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cellen geinjecteerd in lethaal bestraalde muizen. Acht weken na reconstitutie 
van het beenmerg ondergingen de muizen bilaterale nier IRI. We vonden 
functionele bescherming tegen IRI door overexpressie van miR-126 zoals 
aangetoond met verlaagde ureum levels. Bovendien waren schademarkers 
We demonstreerden dat een verhoogd aantal endotheel cellen afkomstig zijn 
uit het beenmerg, een observatie kloppend met de verhoging in circulerende 
hematopoietische stam- en progenitorcellen. We hebben aangetoond dat 
miR-126 CXCR4 expressie verlaagt op deze cellen, welke een stimulus is om 
in het beenmerg te blijven, waardoor deze cellen dus makkelijker migreren uit 
het beenmerg. We bevestigden de vasculaire rol van hematopoietische miR-
126 in een matrigel assay, waarin overexpressie van miR-126 resulteerde in 
verhoogde neovascularizatie. Deze bevindingen suggereren dat overexpressie 
van miR-126 in het hematopoietische compartement beschermt tegen nier 
ischemie/reperfusie schade door stimulatie van hematopoietische progenitor 
cel mobilizatie wat leidt tot een verbetering van de microvasculatuur in de 
nier.
In Hoofdstuk 5
dat, tijdens nefrogenese, FoxD1-positieve mesenchymale cellen uitgroeien 
tot volwassen interstitiele pericyten. Deze FoxD1-afkomstige interstitiele 
zijn in FoxD1-afkomstige interstitiele cellen (dsRed positief) die geisoleerd 
nieren. In vitro hebben we aangetoond dat miR-132 inhibitie resulteert in 
Sirt1 en downstream cyclooxygenase-2 (Cox2). In vivo miR-132 inhibitie 
van collageen depositie in vergelijking tot scramblemir controles, terwijl er 
nog geen verschil waargenomen werd na 5 dagen. Daarnaast demonstreren 
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vergelijkbaar afneemt, wat bevestigd wordt door zowel western blot als qRT-
PCR analyses. Echter, geen verschil in capillaire dichtheid werd waargenomen 
en verrassenderwijs was miR-132 inhibitie geassocieerd met verlaagde Sirt1 
levels. We hebben echter wel aangetoond dat het remmen van miR-132 anti-
proliferatieve effecten heeft wat suggereert dat miR-132 een belangrijke rol 
In Hoofdstuk 6 beschrijven we een rol voor miR-132 in water reabsorptie. 
De collecting duct cellen van onze nieren zijn kritiek in deze reabsorptie en 
homeostase van waterlevels in het bloed, daar het binden van vasopressine 
(anti-diuretisch hormoon) aan de V2-receptor en de daaropvolgende 
duct cellen tegenwerkt door het induceren van internalizatie en lysosomale 
in 
vitro
in opregulatie van Cox2. MiR-132 inhibitie in vivo in muizen leidde tot een 
collecting duct cellen verstoord. Dit resulteerde uiteindelijke in acute diurese 
en gewichtsverlies. Deze data demonstreert een essentiele rol voor miR-132 
in de waterhuishouding.
Tenslotte geeft Hoofdstuk 7 een beschouwing van alle studies beschreven in 
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